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Chapter 1
“When persons in good health are suddenly seized with 
pains in the head, and straightway are laid down speechless, 
and breathe with stertor, they die in seven days.” 
Hippocrates 460-370-BC, Aphorisms on Apoplexy1
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Historical perspective
The clinical presentation of aneurysmal subarachnoid hemorrhage (aSAH) followed by 
subsequent delayed neurological deterioration is likely to have already been described by 
Hippocrates almost 2,500 years ago 1. Millennia later, today’s sufferers of aSAH still have a 
high risk of morbidity and mortality during the course of the disease, even after surviving 
the initial bleed. 
In 1962, Tappura demonstrated that conservative treatment of aSAH is ineffective. In his study 
of patients who survived the initial hemorrhage, 55% suffered from aneurysmal rebleeding 
and 75% died as a result of the disease 2. By the late 1960s, the results from the first Cooperative 
Study of Intracranial Aneurysms and Subarachnoid Hemorrhage were published in a 
monograph, revealing a clear benefit of aneurysm ligation over conservative management 3, 4. 
Although direct clipping was generally considered the best treatment for most aneurysms 
by the late 1970s, the question of when to perform surgery was not definitively answered 5. 
Vast improvements have been made in the operative results of aneurysm clipping, but initially 
this was not reflected in a proportional improvement of overall disease management as 
too many patients experienced rebleeding and delayed cerebral ischemia (DCI) during the 
waiting period. Aneurysm surgery was considered more effective after a period of medical 
stabilization, which seemed to reduce the risk of the postoperative ischemic complications, 
often encountered after early surgery 6, 7. In 1965, Kagstrom et al. demonstrated DCI usually 
occurs at least three days after the initial subarachnoid hemorrhage, and is not restricted 
to patients who undergo surgical clipping 8. Simultaneously, the mortality rate associated 
with aneurysm clipping decreased to a point that further microsurgical improvements 
could be directed towards reducing morbidity. Lougheed, Yaşargil, and others developed 
microsurgical techniques for aneurysm closure, while technical advances included improved 
aneurysm clips created by Norlén and Olivecrona 5, 6. The value of medical management 
in prevention of cerebral ischemia had shown to have limited value; only oral Nimodipine 
treatments were found to be beneficial. Momentum therefore shifted towards early aneurysm 
closure to improve patient outcome. A series of early and ultra-early surgeries performed in 
good-grade patients improved mortality and morbidity rates 9; moreover, the International 
Cooperative Study on the Timing of Aneurysm Surgery demonstrated excellent results when 
performing early surgeries in good-grade patients with aSAH 10. A decade later, the benefits 
of early clipping have been extended to patients with lower clinical grades, and today most 
centers adhere to an ultra-early (within 24 hours) treatment protocol for aneurysm closure.
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Chapter 1
Acute management of subarachnoid hemorrhage
As the temporal focus of disease management shifted toward the first 24 hours following ictus, it 
has become clear that early medical management and decision-making is likely to influence the 
later course of the disease as is reflected in our pathophysiological concepts of aSAH. Commonly, 
two phases are distinguished in the course of aSAH: the initial pathophysiological changes 
within the first three days were termed “early brain injury” (EBI), whereas DCI describes the 
complex of issues that occur later in the course of the disease. Previously, DCI was considered 
the most important determinant of patient outcome following aSAH and most animal studies 
therefore focused on the prevention of this secondary complication; however, the failure to 
translate the results of animal studies into humans has forced us to reevaluate our understanding 
of the complex pathophysiological processes following aSAH. Indeed, a substantial amount 
of evidence indicates that EBI begins at the aneurysm rupture and evolves over time, and is 
therefore an important prognostic factor for the occurrence of DCI and poor patient outcomes. 
Rather than being an epiphenomenon of an associated process, a causal connection between 
EBI and DCI would mean that future therapies should more specifically address EBI. 
The acute phase of aSAH is a complex multifaceted disorder and patients are at risk for a host 
of secondary insults. Besides the direct risks presented by EBI and DCI, two other major early 
complications of aSAH significantly worsen a patient’s prognosis; aneurysmal rebleeding and 
other medical complications, including cardiac and pulmonary complications 11. Poor-grade 
aSAH is an independent predictor for myocardial necrosis, suggesting that cardiac injury after 
subarachnoid hemorrhage is neutrally mediated 12. Cardiac complications following aSAH are 
associated with poor outcomes and the resulting hypoxia and hypotension are important factors 
for DCI 13, 14. Treatment aimed at minimizing early adverse cardiovascular events therefore 
deserves further study. Cardiopulmonary consequences which might occur in response to EBI 
can also delay the diagnostic process and complicate the acute treatment of aSAH.
The risk of aneurysmal rebleeding is highest immediately after the hemorrhage and declines 
over time. In the hours following ictus, an estimated 5.8–15% of patients experience a sudden 
clinical deterioration due to aneurysmal rebleeding 15, 16. Patients who survive the first day 
have a rebleeding risk of 1.2% during the next 48 hours, with a cumulative risk of 40% without 
intervention 16, 17. The prognosis after rebleeding is significantly worse: 80% of these patients 
die or remain disabled 18. Rebleeding is definitively prevented by an aneurysm obliteration, 
either using a surgical or endovascular approach. Prior to aneurysm repair, factors associated 
with rebleeding should be avoided and used in the clinical risk assessment of individual 
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patients. Despite all efforts, the pretreatment aneurysmal rebleeding remains an unresolved 
concern as the risk of its occurrence must to be balanced against concurrent challenges, 
such as the treatment of acute hydrocephalus and the timing of aneurysmal obliteration.  
Thesis outline
This thesis evaluates several aspects and impacts of medical decisions made in the early 
phase of disease for patients suffering from aSAH. First, we review the pathophysiological 
processes following aSAH. 
Disease-specific incidence rates are often used to evaluate national healthcare programs or 
policy decisions. Studies from countries with exceptional incidence rates are sometimes disre-
garded because of concerns regarding their external validity. In the third chapter we discuss con-
troversies in the epidemiology of SAH and their possible impact on clinical decision-making. 
Ultra-early treatment is currently advised for aSAH but this is sometimes delayed by 
suboptimal logistics or delayed diagnoses. In the fourth chapter we investigate the effect of 
delayed admission to specialized care on the mortality rate of patients with poor-grade aSAH. 
As previously stated, patient outcome after aSAH is strongly related to the prevention of 
aneurysmal rebleeding, which is therefore of paramount importance in the treatment of 
this disease. In chapter five, we sought to determine whether aneurysm size is a predictor 
for aneurysmal rebleeding and should therefore be used in clinical risk assessments. 
Early hydrocephalus is a known complication of aSAH. The initiation of cerebrospinal fluid 
drainage (CSF) is assumed to be a risk factor for aneurysmal rebleeding but a causal relation 
has not yet been proven. The amount of CSF drainage has previously not been correlated 
to aneurysmal rebleeding however, as is discussed in chapter six. 
Emergency aneurysm closure may theoretically reduce the aneurysmal rebleeding rate and 
improve patient outcomes. Previous studies have not been able to provide definitive proof 
that ultra-early or emergency-based treatment protocols result in a clinical benefit and early 
aneurysm closure may actually expose the patient to additional risks. The possible negative 
effects of emergency endovascular aneurysm obliteration on complications and patient 
outcome are evaluated in chapter seven.  
In chapter eight, the various aspects of this thesis are discussed, and I present an outlook 
for the future management of patients with aSAH.
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Abstract
Pathophysiological processes following aneurysmal subarachnoid hemorrhage (aSAH) 
present survivors of the initial bleeding with a high risk of morbidity and mortality during 
the course of the disease. As angiographic vasospasm is strongly associated with delayed 
cerebral ischemia (DCI) and clinical outcome, clinical trials in the last few decades focused on 
prevention of these angiographic spasms. Despite all efforts, no new pharmacological agents 
have shown to improve patient outcome. As such it has become clear that our understanding 
of the pathophysiology of aSAH is incomplete and we need to reevaluate our concepts on the 
complex pathophysiological process following aSAH. Angiographic vasospasm is probably 
important. However, a unifying theory for the pathophysiological changes following aSAH 
has yet not been described. Some of these changes may be causally connected or present 
themselves as an epiphenomenon of an associated process. A causal connection between 
DCI and early brain injury (EBI) would mean that future therapies should address EBI 
more specifically. If the mechanisms following aSAH display no causal pathophysiological 
connection but are rather evoked by the subarachnoid blood and its degradation production, 
multiple treatment strategies addressing the different pathophysiological mechanisms are 
required. The discrepancy between experimental and clinical SAH could be one reason for 
unsuccessful translational results.
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Background
The incidence of non-traumatic subarachnoid hemorrhage (SAH) based on nationwide 
epidemiological data has shown to be more or less homogeneous and displays minor 
differences based on different age distributions, study periods and autopsy rates 1, 2. Cerebral 
aneurysm rupture is the cause of spontaneous SAH in up to 85–98.9% of the patients 2, 3. With 
a mean age of 55 at rupture, the average age is significantly lower compared to other types 
of stroke 3-5. Not just the initial hemorrhage, but also pathophysiological processes following 
aneurysmal subarachnoid hemorrhage (aSAH) present survivors with significant mortality 
and morbidity which have major personal and socio-economic impact 3, 5-10. As angiographic 
vasospasm is strongly associated with delayed cerebral ischemia (DCI) and clinical outcome, 
clinical trials in the last few decades focused on prevention of these angiographic spasms 
11, 12. However despite all efforts, no pharmacological agents have shown to improve 
patient outcome 11. In this respect, we aim to reevaluate some of the recent concepts on the 
pathophysiological mechanisms following aSAH.
The pathophysiology of subarachnoid hemorrhage – an introduction
As aneurysm rupture and early pathophysiological responses usually do not occur under 
medical monitoring, most data regarding the very early phase of aSAH results from 
experimental SAH, observations made during aneurysmal re-rupture in hospitalized aSAH 
patients or post-mortem data. Commonly, two phases are distinguished during the course 
of aSAH: initial pathophysiological changes within the first three days were given the term 
“early brain injury” (EBI), whereas “delayed cerebral ischemia” (DCI) describes a complex 
of reactions that occur later during the course of disease. DCI usually appears 3–4 days after 
ictus, the highest incidence and severity is reached after 6–8 days and usually resolves after 
12–14 days 13, 14. Few case reports document late onset DCI beyond 14 days 15, 16. 
The concept of EBI has been coined more recently and evolved after the full mechanisms of 
action behind angiographic vasospasms resulted in a cornucopia of theories and refers to the 
events that occur in the brain before the development of DCI 17-19. The etiology of EBI lies 
at the pathophysiological mechanisms that have been initiated by the initial bleeding that 
predisposes the brain to secondary injury. It has also been suggested that the etiology of DCI 
and EBI are linked. However, causality between the two processes has not yet been established. 
In contrast, DCI has first been reported over 150 years ago and in the ’70 the association 
between delayed neurological deficits and angiographic vasospasm led to a rational assump-
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tion of causation 14, 20-22. As angiographic vasospasm is strongly associated with DCI and 
clinical outcome, clinical trials in the last few decades focused on prevention of vasospasm 
with the aim to improve clinical outcome. However, DCI is likely to consist of a complex 
pathophysiologic complex involving microvascular dysfunction, thrombosis of cerebral – 
especially cortical vessels, cortical spreading depolarizations and depressions and ischemia 
or inflammatory reactions. 
The following sections will broadly cover the complex pathophysiological mechanisms 
following aSAH. 
Early brain injury
The extravasation of blood in the subarachnoid space leads to intense headache and an 
increase in intracranial pressure (ICP). ICP can rise up to similar values as the diastolic 
blood pressure or more 23-31. ICP usually decreases within 10 to 15 minutes but may also 
be sustained. High levels of ICP and arrest of cerebral circulation might be aggravated by 
mechanical factors such as cerebral edema and acute hydrocephalus as they can increase 
ICP and promote cerebral hypoperfusion 23-31. 
An increase in ICP results in a significant reduction of regional cerebral blood flow (rCBF) 
and cerebral perfusion pressure (CPP). These pathophysiological responses are well docu-
mented under experimental and clinical conditions 23-25, 30-37. Clinical studies assessing early 
cerebral perfusion within 72 hours after ictus described a correlation between the initial 
impairment of perfusion parameters, occurrence of DCI and outcome 38-45. 
Cerebral autoregulation (comprising both pressure autoregulation and chemoregulation) 
seems to be frequently impaired after aSAH and is expected to be a major factor contributing 
to initial rCBF impairment 46-50. It may therefore be a prognostic factor for the occurrence of 
DCI and poor outcome 51-54. Cerebral perfusion impairment is likely to result in functional 
disturbances of the brain: in experimental SAH, raised ICP and cerebral hypoperfusion is 
accompanied by a profound suppression of total EEG power 23, 25, 55. Temporary ischemia may 
underlie the observed impairment of cortical function and total ECoG impairment may be 
the result of global transient ischemia. The observation that electrocorticographic activity 
recovers in parallel to normalization of cerebral perfusion suggests a possible causality 23, 25, 55. 
Alternatively, the neurovascular coupling of cortical activity and rCBF might lead to the 
reduction of rCBF when cortical signaling is disrupted 23, 25.
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Impaired rCBF may lead to either transient global or focal ischemia, which initiates a 
cascade of further pathophysiological events 56-59. Initial hypoxia leads to early metabolic 
failure, disturbed ionic homeostasis and to cytotoxic, ionic and vasogenic cerebral edema 56. 
Moreover, ischemia initiates apoptosis of neurons, astrocytes and vascular cells by activation 
of caspase-dependent and -independent pathways 18, 57, 60-67. These pathways, might be the 
target of new therapeutic strategies that aim at the effects of early brain injury, such as 
hypothermia mediating the caspase-3-, PI3K/AKT- and NF-κB-dependent pathways 68, 69. 
Hypoxia also activates inflammatory pathways and the coagulation system 70-72. 
The steep rise in ICP with subsequent possible herniation and destruction of brain tissue 
contributes to the pathology of aSAH. Physiological responses following aSAH result in 
reduced cerebral perfusion and induce several pathophysiological changes within minutes 
after ictus (Figure 2.1). Many patients with aSAH survive this initial phase but suffer from 
cerebral perfusion impairment due to DCI in a later course of disease which may result in 
further neurological deterioration. 
Angiographic vasospasm and delayed cerebral ischemia
DCI can be reversible or it may progress to cerebral infarction. As many as half of the 
patients suffering from aSAH develop delayed neurological deficits caused by DCI 73-80. In 
2010, Vergouwen et al. proposed a standard definition for DCI and cerebral infarction which 
separates the concept of angiographic vasospasm from DCI, which is a clinical diagnosis, 
and cerebral infarction, a radiological diagnosis 81. 
After the first observation of arterial narrowing following aSAH by Ecker and Riemen-
schneider (1951), angiographic vasospasms were believed to induce a causal chain of 
cerebral hypo perfusion with infarctions, neurological deterioration and poor outcome 82. 
The development of ischemic damage often coincides with angiographic vasospasm 83. 
However, DCI can develop in absence of angiographic vasospasms and angiographic 
vasospasm may resolve without causing ischemic lesions 83, 84. The occurrence of angiographic 
vasospasms is related to the amount of subarachnoid blood and indeed blood breakdown 
products have been shown to induce arterial spasms 84-86. In fact, about 70% of aSAH 
patients show angiographic vasospasms 73-75, 77. However, not all aSAH patients that present 
with angiographic vasospasms develop DCI-related cerebral perfusion impairment and 
the percentage of patients that develop actual neurological deterioration due to DCI lies 
at 30% 73-80, 83, 84.
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Angiographic vasospasm induced ischemia has been regarded as a target for therapeutic 
management of DCI. However, a systematic review of several studies (including the 
CONSCIOUS-1 trail) showed that the pharmacological reduction of angiographic vasospasm 
did not translate into improved clinical outcome 11, 12. The reason for the unsatisfying 
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Figure 2.1 Early Brain Injury (EBI).
The figure depicts the pathophysiological changes occurring within the first 72 hours after aneurysm rupture. 
However, its mechanisms are complex and poorly understood.
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translation of experimental results into clinical practice is unclear and one may only speculate 
about the reasons: one reason for this observation might be that drug side effects may negate 
the benefit of the investigated pharmaceuticals or that insensitive outcome measures result 
in unspecific results 11, 87. However, it seems unlikely that all investigated drugs have side 
effects negating its benefits. Second, the connection between DCI and EBI is unknown: 
EBI-related pathophysiological changes might not be a prerequisite for DCI. Both EBI and 
DCI could present themselves as an epiphenomenon of an associated process that itself is 
the true cause of infarction or independently caused by an associated process 83. In fact, 
fresh subarachnoid blood causes EBI and a cocktail of blood degradation production can 
result in cerebral vasoconstriction and likely also in neuronal dysfunction 86. Conversely, as 
discussed in the previous section, EBI could have a causal relationship with DCI 18, 19. The 
pathophysiological processes during EBI including transient global ischemia might initiate 
the later cerebral ischemia and dysfunction of neuronal signaling after the third day following 
aSAH ictus. Indeed, EBI incorporates several pathophysiological changes such as transient 
global ischemia, apoptosis, early metabolic failure and induction of inflammation, which 
could promote later ischemia and neuronal dysfunction. In this view, a targeted treatment 
of EBI-related pathophysiological changes might also address DCI and treatment of DCI 
alone without treatment of EBI would not improve the clinical results. Whether EBI and 
DCI exhibit a causal pathophysiological connection remains unclear. A final reason for 
the disappointing therapeutic management of DCI might be that the pathophysiological 
mechanisms of DCI go far beyond angiographic vasospasm of the major cerebral vessels 
and an ischemia in the downstream territory. Ischemia seems to be crucial factor during 
DCI as several experimental and clinical studies have suggested (e.g. for experimental 
SAH in mouse models) 23, 88-94. However, various other pathophysiological processes next 
to vasoconstriction of the major cerebral vessels were considered to contribute to ischemia, 
such as microvascular dysfunction, microthrombosis, cortical spreading depolarization and 
inflammation and their possible contribution to the development of DCI in aSAH patients 
are discussed in the following section. 
Microvascular dysfunction 
Angiographic vasospasm of the cerebral microvasculature has been observed in different 
experimental animal models of aSAH 90, 95-97. These microvascular spasms have been reported 
to affect up to 70% of all arterioles and were thought to be caused by blood components, in 
particular oxygenated hemoglobin and partially by breakdown products such as Bilirubin 
Chapter_1_Jasper.indd   25 11-7-2018   15:27:21
Chapter 2
26
oxidation products (BOXes) which have a direct vasospastic effect 98-100. Other factors such 
as swollen astrocytic endfeets, constricted pericytes and cerebral edema might also directly 
narrow small vessels and reduce rCBF 101, 102. 
Recently, the attention has shifted toward the role of pericytes located around cerebral 
arterioles, capillaries and venules 103. Pericytes are considered as the main factor of 
microcirculation regulation in aSAH pathology. Especially the postcapillary system is 
easily compressed and provides little access for therapeutic interventions 103. rCBF may 
even reverse after constriction of pericytes, also known as the no-reflow phenomenon 103. 
Pericyte contraction often leads to their programmed cell death, increased capillary transit 
time heterogeneity and microcirculation shutdown 102, 103. 
Occlusion and narrowing of the microvasculature induces several changes in cerebral 
microcirculation. Maintaining cerebral microcirculation is essential as cerebral oxygenation 
depends on both cerebral blood flow (CBF), and the microscopic distribution of blood, the 
so-called capillary transit time heterogeneity (CTH) 102. Elevated CTH after aSAH could 
therefore lead to tissue hypoxia in the absence of severe CBF reduction. Paradoxically, 
reduction in CBF improves brain oxygenation if CTH is critically elevated 102. In this respect, 
angiographic vasospasm and inverted rCBF might reduce CTH and therefore improve net 
tissue oxygen extraction. Whether treatment of increased microcirculatory heterogeneity 
through reduction of CBF results in better long-term clinical outcome remains to be evaluated 
in further clinical and experimental studies. 
Microthrombosis 
Microthrombosis is initiated in the early course of the disease, around the second day 
after aSAH 104. It is the result of a multifactorial process which includes activation of the 
coagulation cascade with a procoagulant activity, impairment of the fibrinolytic activity, 
platelet aggregation in cerebral vessels, arteriole and capillary lumen narrowing by swollen 
astrocytic endfeet and cerebral edema or inflammatory processes 97, 101, 102, 105, 106. It is thought 
to contribute to microvascular dysfunction, increased CTH subsequently leading to ischemia 
and if changes are irreversible, to degenerative changes and permanent neurocognitive 
impairment. 
In autopsy studies microthrombosis has been correlated to DCI and death due to symptomat-
ic angiographic vasospasm 107, 108. In the clinical setting, microthrombosis has also been cor-
related to DCI and microemboli are detected in 30% to 70% of the patients with aSAH 109-111. 
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Indeed the degree of vasoconstriction correlates with the microclot burden 97. Also, there 
seems to be a correlation between the microclot burden and the amount of SAH 107. However, 
not all patients that show histological evidence of cerebral ischemia and microthrombosis 
suffer from clinically apparent DCI 107. 
It is likely that microthrombosis is a significant feature in the pathophysiology of aSAH and a 
possible target for new therapeutic strategies. However, vessels subjected to microthrombosis 
cannot be reached by interventional or surgical efforts. Therapeutic approaches therefore 
mainly focus on a pharmaceutical reduction of clot development. So far limited treatment 
modalities are available. In a meta-analysis analyzing the impact of antiplatelet therapy to 
inhibit microclot formation after aSAH, a trend of improved outcome and reduced secondary 
brain ischemia was found. However, these results did not reach statistical significance 112.
Cortical spreading depolarization, depression and ischemia
Cortical spreading depolarization and depression (CSD) is a well-known phenomenon since 
the 1940’s, and its pathophysiological relevance after aSAH has been investigated in a series 
of experimental and clinical studies mainly by Dreier and coworkers since 1998 62, 113-117. 
Spreading depolarization are propagating, polyphasic slow potential changes and are 
characterized by waves of neuronal depolarization 118, 119. CSD are a cerebral reaction 
to various stimuli such as ion imbalances, trauma, ischemia, electrical stimulation or 
pharmaceutical agents. These brief states of hyperexcitability are followed by depression 
of neuronal activity leading to negative tissue potentials which last at least one minute in 
normal brain tissue 119. CSD causes depression of cortical activity and can be associated with 
cortical spreading or non-spreading depression. Therefore, depression is an epiphenomenon 
of spreading depolarization and is defined as depression of EEG activity propagating with 
a velocity across the brain cortex of 2 to 5 mm/min 113, 118, 119.
CSD are associated with various changes at the cellular level. This includes a disturbance in 
cerebral ion homeostasis: extracellular K+ ion levels increase, whereas Na+, Ca2+ ion levels 
and the pH decrease 119-124. This change in cerebral ion homeostasis results in a net shift of 
water from the extracellular space into neurons causing neuronal edema with a swelling 
and distortion of the dendritic spines 125-127. Excitatory transmitters such as glutatmate and 
aspartate are already released during the depolarization before CSD 119, 121, 122, 128. Elevated 
extracellular K+ and/or the elevated concentration of excitatory transmitters can promote 
propagation of spreading depolarization 129, 130. 
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Cerebral resistance vessels respond with tone alterations. In normal cerebral tissue, CSDs 
induce a net increase in rCBF similar to physiological neuronal activity. This increase 
can result in spreading hyperemia and lasts for several minutes 113. The typical vascular 
response of CSD is a large hyperperfusion followed by a protracted hypoperfusion 119. 
Hyperemia may not be fully adequate to sufficiently supply distant territories. Therefore, 
focal ischemia may occur despite hyperemia 113. In injured cerebral tissue, neuro-vascular 
coupling may further be inverted and CSD may result in a net vasoconstriction, ischemia 
and “spreading ischemia”, with a significant delay of the energy-dependent recovery from 
spreading depolarization 113, 114, 131. In tissue already at risk for progressive damage, this will 
contribute to lesion progression. Local microvascular dysfunction was suggested to be one of 
the major factors contributing to initiation of spreading ischemia and may act together with 
spreading ischemia in lesion progression: spreading ischemia may promote microvascular 
dysfunction and decrease neurovascular reactivity as CSD increases the extracellular K+ 
and reduces NO 114. 
Clinically, electrophysiological evidence exists that CSD occurs in a multitude of patients 
with aSAH and other types of stroke. After aSAH, CSDs were detected by implantation 
of subdural strip electrodes in 18 patients in a prospective multicenter study 117. Nearly 
300 spreading depolarizations were observed in 72% of patients 117. Recurrent spreading 
depolarization occurred in parallel to delayed ischemia induced deficits with positive and 
negative predictive values of 86% and 100%, respectively 117. Furthermore, patients developing 
aSAH-related strokes had associated progressive prolongation of electrocorticographic 
depression periods to > 60 min. 117. In a further prospective multicenter study with 13 SAH 
patients, a subdural electrode was implanted allowing simultaneous recording of the ECoG, 
laser-Doppler flowmetry / rCBF and tissue partial pressure of oxygen ptiO2 117. Isolated CSDs 
are associated with a physiological response resulting in either hyperemia, tissue hyperoxia 
or in an absent or inverse vascular response leading to hypoxemia and hypoxia inverse 
response 115. Clusters of CSDs were detected in patients that developed structural brain 
damage as observed by neuroimaging. They were associated with a significant depression of 
high-frequency-ECoG power, an inverse hemodynamic response and a sustained reduction 
of ptiO2 115, 132. In experimental SAH, inverse hemodynamic response of CSD led to a harmful 
prolongation of depolarization – ultimately to terminal depolarization – and severe spreading 
ischemia and cortical necrosis 62, 115.
In ischemic stroke, cortical activation increases oxygen demand, worsens the supply-demand 
mismatch, and therefore leads to episodic hypoxemia or hypotension and triggers peri-infarct 
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depolarization 133. Therapies targeting CSD, minimizing neuronal activity or inverting the 
hemodynamic response may therefore reduce neuronal damage.
Inflammation
Inflammatory reactions following aSAH have been assumed to play a crucial role in the 
pathophysiology of aSAH, leading to secondary complications associated with angiographic 
vasospasm, EBI and microthrombosis as various inflammatory cascades are being activated 
within the first hours after ictus 134-139. Systemic inflammatory markers such as C-reactive 
protein (CRP) and cytokines may increase in response to aSAH, and are correlated with 
poor clinical outcome 134-138, 140-145. After aSAH, an inflammatory environment develops in 
the subarachnoid space and adjacent brain parenchyma 146. Therefore, several inflammatory 
agents and cascades were hypothesized to promote EBI as well as DCI. 
Sadly, there has been very little success in clinical trials for anti-inflammatory strategies 
with immune-modulating drugs (e.g. steroids, cyclosporin A, Nafamostat) 147-150. With the 
exception of methylprednisolone, none of these pharmacological agents demonstrated 
an improvement in outcome. The use of steroids showed improved patient outcome but 
displayed no effect on either angiographic vasospasm or DCI 147. One of the key factors that 
may complicate clinical trials with immune-modulating drugs is the interpersonal variability 
of the injury and inflammatory response 146. 
A recently published study demonstrates the role of microglial activation after aSAH and 
proposes a new concept referred to as “cortical spreading inflammation”: a mechanism of 
delayed brain injury after aSAH that could offer novel approaches for treatment of the long-
term effects of aSAH. In experimental SAH as well as in aSAH patients, SAH induced an 
intracerebral accumulation of immune cells 71. The spread of immune cells was accompanied 
by an increase of pro-inflammatory cytokines (IL-6; TNFα), axonal and neuronal injury with 
increased intracerebral accumulation of the extracellular amyloid precursor protein and an 
increased rate of neuronal cell death 71. Using a chimeric mouse model for green fluorescent 
protein-labeled peripheral leukocytes, the spreading immune cells were identified as resident 
microglia 71. The authors further conclude that microglia activation causes secondary brain 
injury after aSAH, and microglial activation may therefore correlate with patient outcome 71. 
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Voltage-gated calcium channels in delayed cerebral ischemia. 
Calcium antagonists reduce the risk of DCI related complications after aSAH. Prophylactic 
administration of dihydropyridine L-type calcium (Ca2+) channel antagonists is currently 
recommended in clinical practice for the prevention and treatment of DCI 151. Evidence for 
L-type Ca2+ channel antagonists in the treatment of angiographic vasospasm and DCI is well 
documented 152. However, other types of voltage-gated Ca2+ channels might also contribute 
to the pathophysiology of DCI and provide novel means of treatment. 
In total, ten different types of voltage-gated Ca2+ channels have been described of which only 
four can be attributed to L-type Ca2+ channels (Table 2.1). Recent studies revealed a possible 
significance of other voltage-gated calcium channels (VGCCs): between the fourth and 21st 
day after ictus, HVA VGCCs are significantly decreased and LVA VGCC currents increase 
during experimental SAH in dogs 153. In parallel, protein expression of the Cav1.2 and Cav1.3 
L-type α1 subunits decreases in the dog basilar artery during DCI while expression of Cav3.1, 
Cav3.3 T-type α1 subunits and Cav2.3-containing R-type VGCCs are increased 153. In rabbit 
cerebral artery myocytes, SAH induces an increase of Cav2.3 transcripts and protein as well 
as R-type currents 154. In contrast to the study of Nikitina and coworkers (2010), induction 
of Cav2.3 transcripts and protein occurred only in small resistance cerebral vessels but not 
in the basilar artery 154. SAH may therefore differently impact vessels of different sizes 155, 156. 
Cav2.3 (R-type) VGCCs were suggested to have their pathophysiological significance in 
small diameter arteries 155, 156. The Cav2.3 VGCC antagonist SNX-482 improves DCI-related 
rCBF impairment after SAH in rats 157. SNX-482 reverses oxyHb induced vasoconstriction 
five days after exposure of cultured rabbit cerebral arteries to oxyHb more than L-type 
blocker Diltiazem 99. Furthermore, the beneficial effects of dihydropyridine antagonists 
in prevention and treatment of DCI might not solely be attributed to its effects on L-type 
VGCCs. As Nimodipine reaches comparatively high serum concentrations during treatment, 
its specificity on L-type Ca2+ channels reduces, leading to additionally therapeutic effects on 
other types of voltage-gated Ca2+ channels, such as R-type VGCCs 158-161. 
In addition to R-type VGCCs, T-type Ca2+ channels may also have a functional significance: 
in response to experimentally induced SAH, Cav3.1 and Cav3.3 α1 subunits are upregulated 153. 
However, the functional role of these T-type Ca2+ channels remains unclear. Cisternal 
injection of the T-type blocker Mibefradil did not attenuate angiographic vasospasms as 
assessed by CT angiography in cynomolgus macaques – in contrast to the dihydropyridine 
Nicardipine 162. However, Mibefradil is not a very selective drug that is used in submicromolar 
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Table 2.1 The ion-conducting Cav of voltage-gated calcium channels (Adapted after Kamp et al., 2005) 
Channel type Cav α1 subunit Chromosomal location Typical blocker
High-voltage-activated calcium channel
Cav 1 subfamily: “L”-type calcium channels
L Cav 1.1 α1S 1q31-q32 L-type calcium channel 
antagonists, such as 
1,4-dihydropyridines 
(nimodipine; nicardipine); 
phenylalkylamine (verapamil) or 
benzothiazepine (diltiazem)
L Cav 1.2 α1C 12p13.3
L Cav 1.3 α1D 3p14.3
L Cav 1.4 α1F Xp11.23
Cav 2 subfamily: “non L”-type calcium channels
P/Q Cav 2.1 α1A 19p13.1-p13.2 ω-agatoxin IVA, ω-agatoxin IVB
N Cav 2.2 α1B 9q34 ω -conotoxin-GIVA and MVIIA
E-/R- Cav 2.3 α1E 1q25-q31 SNX-482
Low-voltage-activated calcium channel
Cav 3 subfamily: “T”-type calcium channels
T Cav 3.1 α1G 17q22 Non selective antagonists such 
as Ni+, kurtoxin, Protoxin I&II, 
amiloride, mibefradil
T Cav 3.2 α1H 16p13.3
T Cav 3.3 α1I 22q12.3-q13.2
concentrations used to block T-type channels. As SAH leads to a cell depolarization, T-type 
VGCCs may further be inactivated at resting membrane potentials around −75 to −65 mV. 
Clinical significance of voltage-gated calcium channel blockade in the treatment of 
delayed cerebral ischemia 
The dihydropyridine L-type VGCC blockers are the only pharmaceuticals which improve 
clinical outcome and reduce DCI after aSAH 152. Nimodipine is a lipophilic dihydrophyridine 
L-type VGCC blocker and was introduced for the treatment of cerebral disorders in Europe in 
1985 and approved three years later by the US Food and Drug Administration 20. Nimodipine 
is administered either orally or intra-venously. A meta-analysis and Cochrane Review 
showed the beneficial effect of VGCC antagonists following aSAH. L-type Ca2+ channel 
antagonists reduce the risk of poor outcome (relative risk: 0.81; 95% confidence interval 
0.72–0.92; number need to treat: 19) by preventing secondary ischemia 152. Furthermore, 
administration of VGCC blockers causes a favorable trend towards improvement of case 
fatality 152. The pathophysiological mechanism through which dihydropyridines prevent 
secondary ischemia and subsequently improve outcome following aSAH has not been 
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clearly identified. It has been proposed Nimodipin exerts its effect through changes in rCBF, 
reduction of angiographic microvasospasms, cortical spreading ischemia and microthrombi 
formation 62, 106, 163, 164. Additionally, a possible neuro-protective effect of dihydropyridines has 
been discussed. However this concept remains controversial as its application in treatment of 
acute ischemic stroke has shown no beneficial effect on clinical outcome or case fatality 165.
Although oral or intravenously administrated dihydropyridine antagonists show a benefit 
following aSAH, they are not capable of completely preventing DCI. Intrathecal application 
of dihydropyridines was considered to be a promising alternative to improve effectivity 
compared to oral or intravenous application. Intrathecal administration of Nimodipine 
was successfully evaluated in experimental SAH in the 1980s 166-169. Later, Nicardipine, 
another dihydropyridine L-type VGCC antagonist, was formulated in prolonged-release 
implants. Intrathecal application of these Nicardipine prolonged-release implants 
was analyzed in a few retrospective studies and may reduce the risk of angiographic 
vasospasms, DCI associated neurological deficits and secondary brain ischemic lesions 170-174. 
More recently, Nimodipine was formulated in prolonged-release microparticles for intra-
thecal application. Intrathecal application of EG-1962 Nimodipine prolonged-release 
microparticles reduces angiographic vasospasm in experimental SAH in a rat SAH model 175. 
More importantly, the recently published NEWTON trial (Nimodipine Microparticles to 
Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage) showed 
that intrathecal application was safe and associated with not only a reduced DCI and rescue 
therapy but also improved clinical outcome as measured by the extended Glasgow Outcome 
Score 176, 177. 
Subcellular organelles
The importance of the functional disturbance of subcellular organelles in the pathophysiology 
of aSAH is gaining interest and could provide novel modes of treatment for patients with 
aSAH. Most of the available data stems from preclinical studies but shows that the nucleus, 
the endoplasmatic reticulum (ER), mitochondria and the autophagy-lysosomal system 
display alternate functions during the course of aSAH and could be implicated in its 
pathophysiology 178. Nuclear signaling pathways such as the factor-erythroid 2-related factor 
2 (Nrf2)– antioxidant response element (ARE), and NF-κB signaling are involved in various 
CNS disorders and play a role in the pathogenesis of EBI and angiographic vasospasm in 
experimental SAH 178-180. However, the functional role of these pathways remains unclear 
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and further in-vivo experiments are needed to elucidate the effect of possible agonist or 
antagonist on the course of disease. In neurons, activation of autophagy has been detected 
during EBI 181. Although autophagy is key to cell homeostasis, excessive autophagy can induce 
cell death and is linked to aSAH 178, 182, 183. Moreover, in response to lethal conditions ER 
stress can result in apoptosis and it is hypothesized this may result in apoptosis of endothelial 
cells and results in disruption of the blood-brain-barrier 178, 184. More research is needed to 
establish the exact roles of these organelles in aSAH and may lead to translational results 
into clinical practice. The clinical impact could be significant as a multimodal approach 
that focuses on subcellular organelles has the potential of being highly effective since these 
organelles are interrelated components. 
Perspective and limitations
A unifying theory explaining all the pathophysiological changes following aSAH has 
not yet been described. First, several new concepts and mechanisms were described and 
brought forward during the last two decades. Some are quite new and their clinical value 
(e.g. of microcirculatory dysfunction, CTH or cortical spreading inflammation) has to 
be evaluated in further studies. A clinical impact of cortical spreading depolarization, 
depression and ischemia or EBI is documented and the role of angiographic vasospasms 
was questioned as described above. Second, it remains unknown how these different 
pathophysiological mechanisms following aSAH are connected. As previously discussed, 
some of them may be causally connected or present themselves as an epiphenomenon of 
an associated process. Further studies are required. If all the mechanisms following aSAH 
have no causal pathophysiological connection and are solely evoked by the subarachnoid 
blood and its degradation production, multiple treatment strategies addressing the different 
pathophysiological mechanisms are required. If there is a causal connection between DCI 
and EBI, future therapies should address EBI more specifically. Next, experimental SAH and 
animal models are used to resemble the human condition and to study pathophysiological 
changes following aSAH and the effect of pharmaceuticals and interventions. However, these 
experimental findings might not necessarily mimic the human condition: originating from 
a study comparing inflammatory changes in mice and humans, a large debate questioned 
the scientific value of certain animal models of human diseases. Although data from 
inflammatory diseases do not necessarily translate to hemorrhagic stroke, pathophysiological 
changes after experimental SAH will not completely match human conditions. A recent 
meta-analysis aimed to determine case fatality in mouse DCI models, to compare mortality 
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in mouse DCI models to case fatality in human aSAH patients and to identify factors 
influencing mouse mortality. The study described a significant lower mean overall mortality 
rate in mouse DCI models compared to human case fatality rates following aSAH and 
identified the chosen experimental SAH model (endovascular vs. injection model) as the 
only significant predictor for mouse mortality after 48 hours 185. Further analyses are required 
to establish whether and to which extent different DCI models affect mortality and reflect 
human pathophysiology.
Conclusion
A unifying theory for the pathophysiological changes following aSAH has yet not been 
described. Angiographic vasospasm is probably important. Some changes may be causally 
connected or present themselves as an epiphenomenon of an associated process. A causal 
connection between DCI and EBI would mean that future therapies should address EBI 
more specifically. If the mechanisms following aSAH display no causal pathophysiological 
connection but are rather evoked by the subarachnoid blood and its degradation production, 
multiple treatment strategies addressing the different pathophysiological mechanisms are 
required. The discrepancy between experimental and clinical aSAH could be one reason 
for unsuccessful translational results.
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Abstract
Background
Nordic countries are the primary source for nationwide data on the incidence of subarachnoid 
hemorrhage (SAH). Reliable estimates of national incidence rates of SAH in other countries 
are lacking, yet studies from Nordic countries with exceptional incidence rate are sometimes 
disregarded because of concerns regarding external validity. Autopsies are rarely performed 
for sudden deaths, therefore estimates of the SAH incidence commonly reflect the hospital 
discharge rates. Our aim was to estimate the nationwide incidence of non-traumatic SAH 
in Germany using a national hospital discharge register.
Methods
The German federal statistical office provided the number of patients discharged from all 
German hospitals between 2010 and 2013 with the primary diagnosis of non-traumatic SAH 
(ICD Code I60.0–I60.9) and corresponding age distribution. Age standardised attack rates 
of non-traumatic SAH were calculated using the 2011 German demographic distribution. 
Results
Between 2010 and 2013, the overall age standardized incidence rate of non-traumatic SAH 
was 11.3 per 100,000 person-years and reached a maximum of 22.1 per 100,000 person-
years in the oldest age group. The absolute number of SAH was highest in the group aged 
50–55 years. The distribution of intracranial aneurysms displayed a propensity towards the 
posterior circulation with advancing age (p<0.001), although in absolute numbers SAH 
originated mostly from the anterior circulation. 
Conclusions
Our estimate of the German nationwide attack rate suggests that the incidence of non-
traumatic SAH is more homogeneous than previously assumed. Rejecting the external 
validity of studies from countries believed to display an exceptional incidence rates may 
therefore not be justified.
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Background
The global incidence rate of subarachnoid hemorrhage (SAH) is approximately 8 per 100,000 
person-years and geographical differences between countries have been reported in smaller 
cohorts 1. Nordic countries are the primary source for nationwide epidemiologic data on 
the incidence of SAH and have shown to be more or less homogeneous. The incidence rates 
display minor differences based on age differences in the cohorts, different study periods 
and autopsy rates 2-7. SAH has been reported to originate from intracranial aneurysms in 
as high as 98.9% of the cases and harbouring an intracranial aneurysm is not a lifetime 
condition but is rather considered a dynamic pathology that develops during life 7, 8. 
Other cohorts with a different risk factor profile are likely to display different incidence rates. 
However, other than Nordic studies, little detailed reports on nationwide incidence rates of 
SAH are available for comparison. Comparing international incidence rates allows testing 
hypothesis about the causality of SAH. Moreover, disease-specific incidence rates are often 
used to evaluate national healthcare programmes or policy decisions and sometimes studies 
from countries with exceptional incidence rate are disregarded because of the concerns 
regarding external validity 6, 9. Very few studies take into account out-of-hospitals deaths 
from SAH, like Nordic studies, because autopsies are rarely performed for sudden deaths. 
Therefore, estimates of the SAH incidence commonly reflect the hospital discharge rates 6. 
The aim of this study was to estimate the nationwide incidence of SAH in Germany using 
a national hospital discharge register.
Methods
Identification of SAH patients
Data was provided by the German Federal Statistical Office (Statistisches Bundesamt, 
Wiesbaden). A discharge diagnosis using International Classification of Diseases (ICD) 
codes is legally required to be provided to the statistical office. The database contains all 
public inpatient care of which for each hospital discharge or in-hospital death, one primary 
diagnosis is recorded. These data therefore resemble the admission data. Patients who died 
outside of the hospital are not included. Out of hospital deaths in Germany are registered 
on a municipal level. Retrieving nationwide data would therefore be challenging and not 
warranted based on the validity of the data. The validity of a death registry is dependent on 
the national autopsy rate and the autopsy rate in Germany is extremely low compared to 
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other European countries 10, 11. We identified all records in the database between the 4-year 
period of January first 2010 and December 31st 2013, with a primary diagnosis of non-
traumatic SAH. In absence of a standard definition we included patients classified under 
the rubric I60.0–I60.9 of the ICD, like previously 4. This includes patients with the main 
diagnosis of a non-traumatic SAH from unspecified localization (I60.6–I60.9) and patients 
with non-traumatic SAH assorted to specific parental artery localization (I60.0–I60.5, a. 
carotis interna, a. cerebri media, a. communicans anterior, a. communicans posterior, a. 
basilaris and a. vertebralis). The hospital discharge registry only contains anonymized patient 
data and according to German legislation, analysis of nationwide registries does not require 
institutional ethical review board approval. 
Statistical analysis
Age was categorized according to age groups <1 year, 1–4 years and after that in 5 year 
intervals. The age adjusted discharge rate (ADR) can be used as a surrogate for the age-specific 
incidence, although adjustments have to be made for multiple admissions or lost patients.
Hospital discharge rates (HDR) are expressed as cases per 100,000 persons and ADR were 
calculated. Direct standardization was done using the total German population on the 
median time point of the study period, the 2011 population of Germany on the 31st of 
December (Statistisches Bundesamt, Wiesbaden). The standardized ADR was modelled 
by applying a Poisson regression. Since the presented data are nationwide incidence rates, 
we chose to not report confidence intervals. Binary logistic regression analysis was used 
to identify a trend between anterior of posterior localized intracranial aneurysms across 
the ages groups. The Type I error was set at 0.05 and the tests were 2-tailed. All statistical 
analysis was performed using the R statistical computing package, R version 3.2.2 as released 
on 2015-08-14 (https://r-project.org/).
Results
The source population consisted of all German citizens during 2010–2013 with 321.2 
million cumulative person-years at risk compiled by age category. The mean age at time of 
hemorrhage was 59.0±15.4 years. The census population of Germany on the 31st of December 
2011 was 80,327,900. In total, the database search identified 35,693 patients with a diagnosis 
of non-traumatic SAH (I60.0–I60.9) of which 17,005 (47.6%) were coded to specific parental 
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artery localization (I60.0–I60.5). The absolute number of SAH was highest in the group aged 
50–55 years (4,902 hospital discharges) and shows a rapid decline after the eight decade of 
life (Figure 3.1). 
Overall mean ADR of non-traumatic SAH was 11.3 per 100,000 person-years (Figure 3.2). 
The ARD was 0.05 per 100,000 person-years within the first year, increased exponentially 
from the age group 25–30 years (2.6 per 100,000 person-years) and reaches a plateau around 
Figure 3.1 Absolute number of non-traumatic subarachnoid hemorrhage discharges (I60.0–I60.9) in 
Germany, stratified by age groups.
Figure 3.2 Age adjusted discharge rates (ADR) of non-traumatic subarachnoid hemorrhage (I60.0–I60.9) 
in Germany.
The mean ADR (horizontal line) is 11.3 per 100,000 person years.
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the sixth decade (20.4 per 100,000 person-years, mean overall ADR <60 years was 6.6 per 
100,000 person-years, Figure 3.2). The ADR was highest in the age group of 85–90 years 
(22.1 per 100,000 person-years, Figure 3.2). The maximum ADR of SAH assorted to specific 
parental artery localization (I60.0–I60.5) was reached at the age group of 55–60 years, 10.6 per 
100,000 person-years (mean overall ADR 4.5 per 100,000 person-years, Figure 3.3A). Mean 
overall ADR for I60.6–I60.9 was 6.8 per 100,000 person years (Figure 3.3B). SAH originated 
Figure 3.3A Age adjusted discharge rates (ADR) in Germany of non-traumatic subarachnoid hemorrhage 
assorted to specific parental artery localization (I60.0–I60.5).
The mean ADR (horizontal line) is 4.5 per 100,000 person years.
Figure 3.3B Age adjusted discharge rates (ADR) in Germany of non-traumatic subarachnoid hemorrhage 
from unspecified localization (I60.6–I60.9).
The mean ADR (horizontal line) is 6.8 per 100,000 person years.
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mostly from aneurysms the anterior circulation but its distribution changed with progressing 
age towards the posterior circulation. Binary logistic regression analysis showed a significant 
increase in the incidence of posterior circulation aneurysms with advancing age (Figure 3.4, 
p<0.001). Analysis of specific parental artery aneurysm localizations did not show significant 
differences between age groups.
Discussion
Using a nationwide registry we monitored the German population (80 Million) during 321.2 
million person-years of follow up and identified 35,693 patients with SAH. The overall 
ADR between 2010 and 2013 was 11.3/100,000. The ADR of SAH increased until the sixth 
decade and reached a plateau thereafter. Previous cross-sectional comparisons of different 
populations have shown a divergent epidemiology of SAH 12, 13. Based upon these smaller 
cohorts the age-adjusted average annual SAH attack rate in Germany has been reported to 
be around 5 per 100,000 and was considerably higher in Nordic populations 12-14. Nationwide 
incidence rates of SAH for very few other countries are known but Nordic SAH studies 
show little variation between them, although they vary in case ascertainment 2-5, 7. Using an 
approach previously used to estimate the Swedish national attack rate, our estimate of the 
Figure 3.4 Binary logistic regression analysis on aneurysm localization.
Intracranial aneurysms were classified to either the anterior or posterior circulation. The distribution of 
intracranial aneurysms displayed a propensity towards the posterior circulation with advancing age (p<0.001). 
Each dot symbolizes an individual patient.
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German mean nationwide SAH attack rate is not only higher than previously reported from 
smaller cohorts but also similar to the incidence rate reported by Nordic countries 2-5, 7. In 
Finland, the incidence of SAH between 1989 and 1991 was 13.7 per 100,000 person-years 
and decreased as the European Standard Population (ESP) standardized incidence declined 
from 11.7 in 1998-2000 to 8.9 per 100,000 in 2010–2012 as result of decreasing smoking 
rates 2, 7. In Norway, the reported crude incidence rate was 10.3 per 100,000 person-years, 
and the ESP standardized incidence was 8.7 per 100,000 person years between 1984–2007 3. 
In Sweden the crude incidence of SAH was 12.4 per 100,000 person-years between 1987 
and 2002, and in Denmark the ESP standardized incidence of SAH was 12.3 per 100,000 
person-years in 2002 4, 5. 
Furthermore, our study shows that the prevalence of posterior circulation aneurysms increased 
with advancing age. Elderly with SAH have a higher risk of unfavourable outcome, which can 
be partially appointed to a less active management and more conservative referral patterns 15. 
Indeed, we find a higher rate of unspecified SAH diagnosis with advancing age, which probably 
reflects a reduced propensity to refer this group of patients (Figure 3.3B). The higher rate 
of posterior circulation aneurysms could also be responsible for less favourable outcomes 
as posterior circulation aneurysms are associated with poor clinical outcome and increased 
risk of sudden death after SAH 16, 17. 
The strength of this study is the large number of people that were monitored over an extended 
period of time, although it is impossible to identify the true incidence numbers based on 
a hospital discharge registry 4, 18. Patients with subarachnoid haemorrhage are likely to be 
admitted to the hospital due to the severity of their clinical symptoms, but most sudden 
deaths after SAH take place outside of hospitals. As mentioned previously, very few studies 
take into account out-of-hospitals deaths from SAH, as autopsies are rarely performed for 
sudden deaths and estimates of the SAH incidence therefore commonly reflect the hospital 
discharge rates 4, 6, 19. 
There are several limitations of our study that need to be addressed. Firstly, to our 
knowledge the accuracy of the German electronic health record system has never been 
described. However, the accuracy of several international electronic ICD-coded hospital 
discharge registries for SAH report a positive predictive value ranging from 86–96% 
and has been demonstrated to be the most accurate among various types of stroke 4, 6, 20. 
There is little reason to assume that the German system would by any less accurate and 
results from this database have been published before 18. Nevertheless, it is likely that some 
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episodes of SAH are miscoded in clinical practice. Secondly, we included all diagnoses 
of non-traumatic SAH (I60.0–I60.9), not only the ones of confirmed aneurysmal origin. 
This approach has been described before but presents a source of possible overestimation 
of the incidence of aneurysmal SAH 4. Alternative strategies have been described too but 
are prone to underestimate the true incidence of aneurysmal SAH as the group of patients 
categorized under I60.7–I60.9 may very well include patients with SAH of aneurysmal origin. 
Comparison of the reported incidence rates between studies should be done with caution as 
these differences in study approach could damp possible differences in incidence rates 2-5, 7. 
There is no reason to assume that miscoding rates differ between age groups and therefore 
does not influence the internal validity of our study. Also, since we only included patient 
with SAH as the primary diagnosis we might have missed true episodes of SAH that may 
have had SAH as a secondary diagnosis. This source of underestimation seems negligible 
due the severity of the disease. Thirdly, our study cannot be regarded as a true incidence 
study since we did not include death certificates in our analysis. This is in contrast to the 
previously mentioned Nordic cohorts. Registration of deaths in Germany is organized on 
a municipal level and the autopsy rates in Germany (3%) are frighteningly low compared 
to other European countries 11, 21. Since the validity of a death registry is highly dependent 
on the autopsy rate, acquisition of this data for our cohort was not warranted. This could 
have lead to an significant underestimation of the incidence rates as an estimated 12.4% of 
all SAH episodes result in sudden death before patients reach the hospital 22. On the other 
hand, including death certificates could also lead to an overestimation of the incidence rate 4. 
Nevertheless, extrapolating our reported overall discharge rate of non-traumatic SAH with 
an estimated 12% rate of out of hospital deaths, would yield a figure very similar to previous 
reported Norwegian, Swedish and Finnish cohorts that did include a death register 3, 4, 7. 
Differences in autopsy rates between the death registers used in these studies need to be 
considered when interpreting their results. Another source of overestimation might be 
recurrent admissions or admissions after referrals that have been miscoded as first events. 
In general the effect of over- and underestimation seems minimal as our findings are in 
concordance with previous studies 2-5, 7. Lastly, we only adjusted for age as data on other risk 
factor such as smoking and high blood pressure was unavailable.  
Despite the limitations we think that our study presents interesting findings. Nationwide 
incidence data on SAH has already shown that Finland does not have an increased incidence 
of SAH compared to other Nordic countries 2-7. To our knowledge this is the first nationwide 
epidemiologic evidence that exists about the incidence of SAH apart from the nationwide 
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Nordic SAH studies and suggests that the incidence rate of SAH in much more homogenous 
than previously reported 12, 13. Minor differences between the reported incidence rates of SAH 
are likely to result from a different prevalence of risk factors for SAH such as smoking and 
blood pressure level, autopsy rates and population structure 6, 7. Nevertheless, Finnish SAH 
studies have previously been excluded from pooled analysis and its application to reference 
populations has been questioned based on the high SAH incidence and concerns regarding 
the external validity 6. Apart from the risk of publication bias, this approach might also alter 
conclusions from pooled analysis such as the PHASES risk prediction chart for unruptured 
intracranial aneurysms and could consequently lead to misguided treatment decisions 6, 9.
Conclusions
Nationwide attack rates of SAH from Nordic countries have shown to be more or less homo-
geneous but vary in case ascertainment. Our estimate of the German nationwide attack rate 
suggests that the incidence of non-traumatic SAH is more homogeneous than previously 
assumed. Rejecting the external validity of studies from countries believed to display an 
exceptional incidence rates may therefore not be justified. 
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Abstract
Background
Time has shown to be a relevant factor in the prognosis for a multitude of clinical conditions. 
The current analysis aimed to establish whether delayed admission to specialized care 
is a risk factor for increased mortality in case of poor grade aneurysmal subarachnoid 
hemorrhage (aSAH).
Material and methods
Consecutive patients with aSAH were enrolled retrospec tively if they had a World Federation 
of Neurological Surgeons Grading System (WFNS) - Grade of 5. Predictor variables for 
in-hospital mortality reflecting demographic, spatial, temporal treatment and neurological 
factors were recorded from hospital records and emergency doctor’s reports. We performed 
statistical analysis on the relationships between the predictor variables and in-hospital 
mortality. 
Results
The study included 61 patients with an average age of 58 years. The overall in hospital mortal-
ity rate was 28% (17/61 patients). A delayed transport to specialized neurosurgical care was 
associated with increased in-hospital mortality. Transportation time was mainly prolonged 
in cases where an alternative diagnosis was made by the emergency physician. Mortality 
was highest in patients with cardiovascular complications of subarachnoid hemorrhage. 
Conclusion
Delayed admission to specialized care is associated with a higher mortality rate in patients 
with poor grade aSAH. Accompanying non-neurosurgical, mainly cardiac complications 
might be a significant factor leading to delayed admission. The emergency physician should 
be aware that cardiovascular abnormalities are a relevant complication and sometimes the 
first identified clinical feature of poor grade aSAH.
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Introduction
There have been several studies that aimed to identify risk factors in order to reduce mortality 
in patients with intracranial pathology 1-4. Most of these prognostic factors for outcome 
are present at ictus and cannot be influenced by medical management. However, for some 
conditions such as ischemic stroke and myocardial infarction a substantial contribution 
to outcome can be made by reducing time until admission 1. For traumatic acute subdural 
hematoma too, it has been shown that if all patients were taken directly to hospitals equipped 
to diagnose and treat the hematoma within mere hours after the injury, mortality rates 
could be reduced 1.
In most cases of traumatic brain injury the possibility of intracranial pathology cannot be 
overseen and transport of a patient to a non-trauma center is seldom 1. One of the problems 
the emergency doctor faces in case of a non-traumatic loss of consciousness is to exclude 
intracranial pathology. If the patient arrives in a hospital without a neurosurgery department, 
cerebral computed tomography (CCT) has to be performed alongside other diagnostic 
procedures and in case of aneurysmal subarachnoid hemorrhage (aSAH) the patient has 
to be referred to a neurosurgical department. Delay of transport to a neurosurgical clinic 
is therefore expected to be more likely. By studying the time from emergency call of an 
unconscious patient with an aSAH until arrival in our neurosurgical department we seek 
to identify whether the delay from ictus to neurosurgical admission is a risk factor for 
increased mortality in aSAH.
Methods
Study population
We conducted a retrospective study of patients with aSAH admitted to our neurosurgical 
department between January 1st 2012 and December 31st 2014. The inclusion criteria for this 
study were as follows: subarachnoid hemorrhage demonstrated by CCT and the presence of 
an aneurysm confirmed by cerebral digital subtraction angiography or CT-angiography. Only 
patients with a World Federation of Neurological Surgeons Grading System (WFNS)- Scale for 
subarachnoid hemorrhage of 5 upon arrival of the emergency response team were included. 
The primary outcome of the study was in-hospital mortality. The study was approved by the 
Heinrich Heine University Institutional Ethics Committee, study number 5277. 
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Treatment protocol
Patients were admitted to a specialized intensive care unit (ICU) and given treatment 
according to a standardized management guidelines 2, 3. Patients are monitored on our ICU 
under a minimal touch regime until aneurysm closure. Aneurysm closure was preferably 
performed within 24 hours. Antifibrinolytic agents are only applied when definite aneurysm 
closure cannot be achieved within 36 hours 2. Emergency surgery was performed if hematoma 
evacuation or decompressive hemicraniectomy was indicated. In all patients with a WFNS 
grade 4 or 5, invasive neuromonitoring with an intraventricular catheter is initiated. The 
systolic blood pressure is lowered not to exceed 140 mmHg. Prophylactic treatment with 
dihydopyridine L-type calcium channel antagonists is started and all patients undergo serial 
perfusion computed tomography (PCT) during their stay on the ICU. 
Clinical and radiological data collection
For all included patients, demographic data, suspected initial diagnosis and clinical features 
at onset were obtained from emergency response teams protocols. Neurological status was 
assessed with the WFNS grade and Glasgow Coma Scale (GCS). Significant clinical interval 
changes and interventions during hospitalization were retrieved from patient charts and 
documentation from the primary hospitals and our patient records. Admission CCT scans 
from the referring hospital and our own clinic were also assessed.  
Definition of outcome parameters 
In hospital mortality or neurological devastation leading to withdrawal of care were identified 
after analyzing all available clinical and radiological data. In hospital mortality was defined 
as death within 30 days after admission. The distance from the initial location of onset 
to our neurosurgical department was determined as the shortest distance in kilometers 
(km). Distance was measured using a desktop web mapping service: http://maps.google.
de. Transportation time was determined by retrieving the emergency units response time 
and emergency room admission time from the treatment protocols. Rush hour was defined 
from 6:00 to 9:00 a.m., and 4:00 to 7:00 p.m. 
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Statistical analysis
Categorical data are presented as counts and percentages and continuous variables as mean 
with standard deviation (SD) or median with interquartile range (IQR) depending on the 
normality of data. The statistical analysis was performed with t-test and chi square test. 
Statistical significance was set at p<0.05. All statistical analysis was performed using the R 
statistical computing package, R version 3.2.2 as released on 2015-08-14 (https://r-project.org/).
Results
Overall mortality
In total, 356 patients had been admitted with an aSAH during the study period. Sixty-one 
patients (17%) fulfilled the inclusion criteria. We could complete our database for 51 patients. 
In the remaining ten patients we could review the parameters for which the information was 
available. Excluding these patients from the analysis did not alter the results. The mean age 
was 58.1 years (22–84 y). Twenty patients were male and 41 female (m:f, 1:2). The overall 
in hospital mortality rate was 28% (17/61 patients). Forty patients displayed an aneurysm 
located on the anterior circulation of the circle of Willis and mortality was 35% (14/40). The 
remaining 21 patients with an aneurysm on the posterior circle had a mortality of 14% (3/21, 
not significant). Figure 4.1 shows the distribution of aneurysms in the brain as well as the 
mortality rate for each location.
Figure 4.1 Distribution of aneurysm location in the study population.
Most aneurysms were located in the anterior communicans artery. Aneurysms located on the anterior circulation 
were twice as common as aneurysms on the posterior circulation. The blue columns represent the absolute 
numbers, whereas the red columns represent fatalities. The mortality difference between anterior and posterior 
circulation aneurysms failed to show statistical significance.
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Figure 4.2 Association between mortality and onset-to-neurosurgical center time.
A Onset-to-neurosurgical admission time was significantly longer when the transport was indirect, i.e. when 
a local hospital without a neurosurgical department was targeted first (p<0.001).
B In fatal cases the mean transport time to the neurosurgical center was significantly longer compared to 
patients who survived (230 vs. 115 minutes, p<0.05). 
C When a non-neurosurgical center was targeted first and cranial imaging was delayed, mortality increased. 
The transportation time was significantly higher in the mortality group then in the survival group (300 vs. 
150 minutes, p<0.05). 
D When patients were directly transferred to our clinic there was no difference in transport time between 
the 2 groups.
Transport time and mortality
The time required from arrival of the first medical response team until admission to our 
neurosurgical department is depicted in Figure 4.2A. Thirty-five patients (57%) were admitted 
to another hospital for further diagnostics and transported to our hospital after CCT showed 
subarachnoid hemorrhage, whereas 26 patients were admitted to our hospital directly (mean 
transportation time 262 vs. 71 minutes p<0.001). There was a significantly higher transport 
time in the mortality group compared to the survival group (Figure 4.2B, mean transport time 
230 vs 115 minutes p<0.05). Longer hospital stay in the primary hospital was also associated 
with increased mortality (mean 300 vs. 150 minutes, p<0.05, Figure 4.2C). However, there was 
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no significant difference in transport time between the death- and survival group when patients 
were transported directly to our neurosurgical department (Figure 4.2D, 60 vs. 79 minutes).
Initiation of neurosurgical treatment and mortality
Shorter transportation time did not result in faster initiation of neurosurgical treatment for 
aneurysm closure. Emergency surgery did not influence the outcome in any direction. Patients 
without external ventricular drain showed a higher mortality. However only few patients N=5 
had no ventricular drainage because the therapy had to be discontinued.
Alternative diagnosis and mortality
When aSAH was suspected, mean transport time until admission at the neurosurgical 
department was 79 minutes compared to 220 minutes when alternative pathology was 
suspected (Figure 4.3A, p<0.05). Suspicion of an alternative diagnosis was associated with 
increased mortality (Figure 4.3B). In cases where cardiac pathology was suspected (n=8) 
mortality reached 75% (Figure 4.3B). Four patients received a diagnostic coronary angiography 
and none of them survived. 
Figure 4.3 Ambulance team diagnosis and transport time.
A When aSAH was suspected the onset to neurosurgical admission time was significantly lower compared 
to cases where an alternative diagnosis was made. These patients had a greater chance of first admission to 
a non-neurosurgical hospital (p<0.05).
B The suspicion of an aSAH by the emergency response team was associated with a significantly lower mortality 
rate compared to patients who received an alternative diagnosis (20 vs. 45%). The highest mortality was seen 
in patients diagnosed with a myocardial infarction (75%). The patients who received a cardiac angiography 
had a mortality of 100% (4/4) (p<0.05). 
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Distance to neurosurgical department
Patient mortality was not correlated with the distance from the incident to the neurosurgical 
department. The mean distance in patients who died was 18 km against 25 km in those who 
survived (not significant, Figure 4.4A). Figure 4.5 provides an overview of the area from 
which patients were admitted to our department, as well as the distance and transport times 
between the four university hospitals and three additional Level I trauma centers in the area. 
Transport during rush hour did not affect patient survival (Figure 4.4B).
Discussion
The present study demonstrates that delay of specialized care for poor grade aSAH is cor-
related with increased mortality. Prolonged transport is associated with suspicion of an 
alternative diagnosis by the emergency physician and the highest mortality rates are reached 
in cases where primary cardiac pathology was suspected.  Decreased mortality in patients 
with short or direct transportation was not due to a different neurosurgical intervention 
strategy in our series. 
However medical complications are another main cause of death after aSAH. A reported 
15–23% of in-hospital deaths have been attributed to medical complications 4. Early brain 
injury (EBI) is one of the key aspects in the pathophysiology of SAH as the extravasa tion 
of blood in the subarachnoid space initiates several pathophysiological responses that are 
Figure 4.4 Distance and traffic in association with mortality.
A The distance from location of onset and the neurosurgical department did not play a significant role in 
relation to patient mortality.
B Transport during rush hour did not affect patient mortality. 
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expected to influence patient outcome 5-10. The concomitant increase in intracranial pressure 
is accompanied by a severe impairment of cerebral perfusion 11-21. This reduction of cerebral 
perfusion as measured by the mean transit time is correlated with both the occurrence of 
delayed cerebral ischemia (DCI) and clinical outcome 22-29. The impairment of cerebral blood 
flow can lead to either transient global or focal ischemia, which initiates a cascade of further 
Figure 4.5 Distance maps and distribution of high volume neurosurgical centers in the area.
A The black crosses symbolize patients who were transported directly to our neurosurgical centre. The red 
circles symbolize referring hospitals. The distance is in kilometers (km).
B Distribution of the 4 university hospitals in the area and their distance from our center as well as the travel 
time by ambulance. There are another 3 Level I trauma centers in this area, increasing the number to 7 within 
a radius of 90 km around our center. 
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pathophysiological changes. Early initiation of neuroprotection directed at minimizing EBI 
related pathophysiological changes might reduce the risk of DCI and subsequently improve 
patient outcome 4, 30. This could explain the better outcome of patients with a reduced 
transportation time. 
aSAH has a complex pathophysiology and besides significant neurological damage it 
can also involve systemic organ injury. The high rate of alternative diagnosis in patients 
with prolonged transportation times or indirect admission may reflect additional non-
neurosurgical challenges that often accompany the aSAH and delay transport. In our 
cohort we find the highest mortality rate in patients with suspected cardiovascular com-
plications. aSAH frequently results in myocardial necrosis with release of cardiac enzymes 
which can lead to a coronary angiography before a CCT scan has been performed 31. 
Poor grade aSAH is a strong independent predictor of myocardial necrosis after aSAH 31. 
This finding supports the hypothesis that cardiac injury after aSAH is mainly a neurally 
mediated process with a disturbance of brain-heart connection. The association of troponin 
elevation with stunning of the myocardium, hypotension and poor outcome after aSAH has 
been well documented and supports multimodality monitoring data which has identified 
hypoxia and hypotension as important factors for secondary brain injury 4, 32. Treatment 
aimed at minimizing myocardial toxicity in order to reduce adverse cardiovascular events, 
the risk of DCI and improve outcome therefore deserves further study. 
The present study has several limitations that need to be addressed. Due to the retrospective 
design we could not demonstrate causality between delayed transport and mortality. 
However, the association we found between delayed admission to specialized care and 
increased mortality is in concordance with a previous study which has shown that case 
volume is related to patient outcome 33. Patients with a diagnosis of aSAH on their discharge 
record who initially presented through the emergency department of a hospital with a high 
volume of aSAH cases had significantly lower mortality rates 33. For patients with acute 
intracerebral hemorrhage, admission to a specialized neurosurgical intensive care unit has 
also been associated with reduced mortality 34. Furthermore, we could not demonstrate a 
positive effect of emergency surgery on patient outcome. Multiple studies have shown that 
ultra-early aneurysm closure (<24 hours) or even emergency application of surgical clip 
placement or endovascular coiling results in an reduced incidence of recurrent bleeding and 
improves clinical outcomes 35, 36. Within our ultra-early treatment protocol, patients qualified 
for emergency surgery when hematoma evacuation or decompressive hemicraniectomy was 
indicated. This lack of a uniform treatment protocol for aneurysm closure on an emergency 
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basis is a likely cause why we did not observe reduced mortality after emergency surgery. 
In addition it has to be recognized that our cohort comes from a densely populated area 
with an abundance of medical resources and it is questionable whether our results can be 
transferred to less populated areas. 
Conclusion
In conclusion, the present study demonstrates that delay in specialized care is associated 
with increased mortality in poor grade aSAH. Strategies directed toward minimizing early 
brain injury with prevention and treatment of cardiovascular complications, hold promise 
for further reducing mortality after aSAH. The emergency physician should be aware that 
cardiovascular abnormalities are a relevant complication and sometimes the first identified 
clinical feature of poor grade aSAH. Due to the correlation with malignant aSAH, high level 
of clinical suspicion, prompt recognition and treatment of this complication are necessary. 
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Abstract
Object
Aneurysmal rerupture prior to treatment is a major cause of death and morbidity in aneurysmal 
subarachnoid hemorrhage (aSAH). Recognizing risk factors for aneurysmal rebleeding is particularly 
relevant and might help to identify the aneurysms that benefit from acute treatment. It is uncertain 
if the size of the aneurysm is related to rebleeding. This meta-analysis was performed to evaluate 
whether an association could be determined between aneurysm diameter and the rebleeding rate 
before treatment. Potentially confounding factors such age, aneurysm location, and the presence of 
hypertension were also evaluated.
Methods
The authors systematically searched the PubMed, Embase, and Cochrane databases up to April 3, 
2013, for studies of patients with aSAH that reported the association between aneurysm diameter and 
pretreatment aneurysmal rebleeding. The Grading of Recommendations Assessment, Development 
and Evaluation (GRADE) criteria were used to evaluate study quality. 
Results
Seven studies, representing 2,121 patients, were included in the quantitative analysis. The quality of 
the studies was low in 2 and very low in 5. Almost all of the studies used 10 mm as the cutoff point for 
size among other classes, and only one used 7 mm. An analysis was performed with this best unifiable 
cutoff point. Overall rebleeding occurred in 360 (17.0%) of 2,121 patients (incidence range, from study 
to study, 8.7%–28.4%). The rate of rebleeding in small and large aneurysms was 14.0% and 23.6%, 
respectively. The meta-analysis of the 7 studies revealed that larger size aneurysms were at a higher 
risk for rebleeding (OR 2.56 [95% CI 1.62–4.06]; p=0.00; I2=60%). The sensitivity analysis did not alter 
the results. Five of the 7 studies reported data regarding age; 4 studies provided age-adjusted results 
and identified a persistent relationship between lesion size and the risk of rebleeding. The presence 
of hypertension was reported in two studies and was more prevalent in patients with rebleeding in 
one of these. Location (anterior vs posterior circulation) was reported in 5 studies, while in 4 there 
was no difference in the rebleeding rate. One study identified a lower risk of rebleeding associated 
with posterior location aneurysms. 
Conclusions
This meta-analysis showed that aneurysm size is an important risk factor for aneurysmal rebleeding and 
should be used in the clinical risk assessment of individual patients. The authors’ results confirmed the 
current guidelines and underscored the importance of acute treatment for large ruptured aneurysms.
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Introduction
The incidence of aneurysmal subarachnoid hemorrhage (aSAH) is about 5–10 cases per 
100,000 21, 26. Closure of the aneurysm after initial aSAH is the primary goal to prevent 
aneurysmal rebleeding, which has an associated mortality rate of up to 50% 32. The incidence 
of rebleeding after an aSAH has been estimated to be 14%–17% during the first 24 hours, and 
studies have shown that 87%–92% of all rebleeding occurs within the first 6 hours after the 
initial bleed 9, 32. Endovascular coiling or clipping to secure the aneurysm is advised as early 
after rupture as is feasible to reduce the rate of rebleeding 8. Currently, ultra-early treatment, 
considered to be within 24 hours, is advised for patients in good clinical condition 34. 
Although nonmodifiable causes, such as transfer from other hospitals and late diagnosis, 
might delay treatment, ultra-early treatment can also be difficult due to internal logistics 
issues like limited 24/7 surgical coverage and access to operating theaters and anesthetic 
and nursing staff 34.
Recognizing risk factors for aneurysmal rebleeding is particularly relevant and might help 
to identify the aneurysms that benefit from acute treatment. In recent years, several risk 
factors, such as hypertension and the location and size of the aneurysm, have been shown to 
be associated with rebleeding 9, 10, 19, 28, 37. Biomechanical studies have indicated that cerebral 
aneurysmal rupture occurs when there is a decrease in the ratio of the artery wall thickness 
to the radius of the aneurysm 7. This concept might explain the possible relationship between 
aneurysm diameter and the risk of rebleeding. However, the association between the risk of 
rebleeding and aneurysm size might be confounded by age 28. In particular, older patients 
may have larger aneurysms, and their general condition makes it more likely that treatment 
is postponed, leaving these individuals more prone to rebleeding. This meta-analysis was 
performed to evaluate whether an association could be established between aneurysm 
diameter and rebleeding rate before treatment. Potentially confounding factors like age, 
aneurysm location, and the presence of hypertension were also evaluated.
Methods
Search strategy and selection criteria
The meta-analysis was constructed using the MOOSE guidelines 38. In particular, an inde-
pendent, experienced librarian systematically searched the PubMed, Embase, and Cochrane 
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databases up to April 3, 2013, for studies of patients with aSAH that reported the association 
between aneurysm diameter and pretreatment aneurysmal rebleeding. The search strategy 
is set out in Table 5.1.
Data extraction
Two authors (J.V.L. and H.B.) independently read all titles and abstracts and selected those 
that appeared to be relevant for a full text review without language restrictions. Conference 
abstracts, reviews, meta-analyses, editorials, and animal studies were excluded. From the 
remaining studies, full-text articles were obtained and independently evaluated by two 
of the authors (J.V.L. and H.B.). Studies were deemed to be eligible if they included: 1) 
patients with aSAH in either a prospective or retrospective population-based design; 2) the 
association between aneurysm diameter and the rebleeding rate; and 3) results that included 
or enabled the calculation of an odds ratio. A third author (R.B.) was consulted to resolve 
Table 5.1 Search strategy and results in Pubmed, EMBASE and Cochrane databases
No. of studies
Step Search terms Pubmed                        Embase Cochrane
1 subarachnoid haemorrhage.ti,ab. OR Subarachnoid 
Hemorrhage[Mesh:noexp] OR (subarachnoid.ti,ab. 
AND hemorrhage.ti,ab.) OR subarachnoid hemorrhage.
ti,ab. OR subarachnoid haemorrhages.ti,ab. OR 
subarachnoid hemorrhages.ti,ab. OR SAH.ti,ab. OR 
SAHs.ti,ab. OR subarachnoid hematoma.ti,ab. OR 
subarachnoid bleeding.ti,ab. OR ((Brain Aneurysm.
ti,ab. OR brain aneurysms.ti,ab. OR Cerebral Aneurysm.
ti,ab. OR cerebral Aneurysms.ti,ab. OR "Intracranial 
Aneurysm"[Mesh]) AND (rupture*.ti,ab.)))))†‡
25,423 35,627 998
2 ("Recurrence"[Mesh] OR Recurrence.ti,ab. OR 
Recurrences.ti,ab. OR Rebleed*.ti,ab.)
306,816 339,678 21,206
3 Step 1 AND Step 2 1,844 2,151 75
4 ("Risk"[Mesh] OR Risk.ti,ab. OR sized.ti,ab. OR sizes.ti,ab. 
OR 10 mm.ti,ab. OR 7 mm.ti,ab. OR 5 mm.ti,ab. OR 6 
mm.ti,ab. OR 8 mm.ti,ab. OR 9 mm.ti,ab. OR diameter.
ti,ab.)
1,849,179 2,355,608 111,279
5 Step 3 AND Step 4 610 773 25
6 Limits: none 610 773 25
MeSH = Medical Subject Headings; mm = millimeter; noexp = no explosion of MeSH heading; ti,ab = title/abstract.
† The asterisk in this field indicates that rupture was a major topic of these articles.
‡ Quotation marks indicate that the entire phrase was searched.
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any disagreements. Reference screening was conducted to identify additional studies from 
the full-text articles that were evaluated. Included studies were selected for a quality review. 
The methods recommended by the Grading of Recommendations Assessment, Development 
and Evaluation (GRADE) system for rating the quality of evidence were applied 2, 11-17. 
The ORs and 95% CIs between small and large intracranial aneurysms were extracted or 
calculated. Size categories were then registered. The cutoff between small and large size 
had to be established according to the published data. In cases of overlapping cohorts, we 
excluded the one with the lesser-quality data or, if equal in quality, the one with the fewest 
patients to prevent an artificial increase in effect size.
Statistical analysis
Comprehensive Meta-Analysis software (Version 2.2.046, 2007, Biostat, Inc.) was used to 
perform statistical analysis. The odds ratio for the risk of the rebleeding of small compared 
with large intracranial aneurysms was used as the effect size. Size cutoff was determined based 
on the presence of a (close to) common value across the studies. Both fixed- and random-
effect models were used to calculate the summary ORs and 95% CIs. The significance of the 
overall OR was determined using a Z-test. For the sensitivity analysis, each study was removed 
from the total and the remaining studies were reanalyzed. The Type I error was set at 0.05 
and the tests were 2-tailed. We assessed the heterogeneity between the study estimates using 
the I2 statistic, with thresholds for a low degree of heterogeneity set at 40% 13. The funnel 
plots were inspected, and the Egger test was used to look for evidence of publication bias.
Results
Included studies
The literature search revealed a total of 1,408 records: 610 in PubMed, 773 in Embase, and 25 
in the Cochrane database (Figure 5.1, Table 5.1). An additional study was found by screening 
the references. After the removal of duplicates, we were able to identify 867 studies. Review 
of the abstracts left us with 26 studies for the full-text evaluation 3-6, 9, 10, 18-20, 22-25, 27-31, 33, 35-37, 39, 41. 
Ten studies were excluded because they did not evaluate aneurysm diameter as a risk factor 
for rehemorrhage rate 4, 6, 9, 18, 22, 24, 29, 36, 39, 41. Two other articles were excluded because one was 
a review and the other was an editorial 25, 36. One study was written in Japanese and was thus 
also excluded 31. Four studies used an overlapping cohort, and the one with most appropriate 
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data was selected 5, 19, 20, 27, 28, 30, 35. In total we identified 9 studies that met our inclusion 
criteria 3, 10, 19, 23, 27, 28, 33, 37, 41. Clinical and/or radiological definitions of rebleeding were given in 
8 studies and these are listed in Table 5.2. Only 1 study reported the median time to rebleeding 
and the median time to aneurysm repair 3. Aneurysm size categories were given in 7 studies, 
while 2 others reported the mean size for the lesions in the non-rebleeding group compared 
with the rebleeding group (Table 5.2). Four studies reported on time to treatment or time to 
rebleeding (Table 5.2).
Quality assessment
The methodological quality of the 9 included studies was assessed. Of a total of 45 scores, 
there was no disagreement (Table 5.3). As a consequence of their observational design, all 
of the studies started with a maximal quality score of low. None of the studies were rated 
down based on serious inconsistency, indirectness, imprecision, or publication bias. In 5 
Figure 5.1 Chart showing the results of the literature search.
Pubmed n=610
Cochrane n=25
Embase n=773
Additional records identiﬁed 
trough reference screening
n=1
Records after duplicates removed
n=867
Records screened
n=867
Records excluded
n=841
Full-text asessed for eligibility
n=26
Articles excluded n=17
Review article n=1
Insuﬃcient data n=1
Overlapping data n=4
Editorial/ Abstract n=1
Language (Japanese) n=1
Studies included in qualitative 
synthesis
n=9
Records excluded 
n=2
Studies included in quantitative 
synthesis
n=7  
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studies, however, the quality was rated down because of serious limitations: Adjustment of the 
rebleeding rate for the time after the initial hemorrhage was not performed, or consecutive 
series were not reported 10, 19, 23, 33, 37.
Data analysis
Seven of 9 studies provided core data, making calculation of the OR possible 10, 19, 23, 28, 33, 37, 41. 
Almost all of the studies used 10 mm as the cutoff point for aneurysm size among others 
classes, with only 1 study using 7 mm (Table 5.4). An analysis was performed with this 
best unifiable cutoff point. Overall rebleeding occurred in 360 (17.0%) of 2,121 patients 
(incidence range, from study to study, 8.7%–28.4%). The rate of rebleeding in small and 
large aneurysms was 14.0% and 23.6%, respectively (absolute risk difference 9.6%). The 
meta-analysis of the 7 studies revealed that larger size aneurysms had an overall OR for 
Table 5.4 Rebleeding rates
                                                                      
Authors & Year
Aneurysm size used 
for analysis Rebleeding rate (%)*
Small Large Small Large
Total 
rebleeding
Kassell & Torner, 1983 <10 mm ≥10 mm 49/469 (10.4) 21/195 (10.7) 70/664 (10.5)
Paré et al., 1992 <10 mm ≥10 mm 2/61 (3.3) 13/67 (19.4) 15/128 (11.7)
Beck et al., 2006 NA: reported mean 
size in non-rebleeding 
& rebleeding group; 
6.9±4.7 vs 11.2±9.2 
mm (p=0.002)
NR NR NA 
Plezier et al., 2006 ≤10 mm >10 mm 68/281 (24.2) 22/73 (30.1) 90/354 (25.4)
Inagawa, 2010 <10 mm ≥10 mm 48/205 (23.4) 33/80 (41.3) 81/285 (28.4)
Guo et al., 2011 ≤10 mm >10 mm 18/169 (10.7) 52/157 (33.1) 70/326 (21.5)
Shiue et al., 2011 <10 mm ≥10 mm 13/195 (6.7) 9/59 (15.3) 22/254 (8.7)
Lord et al.,  2012 NA: reported mean 
size in non-rebleeding 
& rebleeding group; 
7 mm (5–10) vs 8 mm 
(6–15) (p=0.001)
NR NR NA (case-
control study)
Tsui et al., 2012 <7 mm ≥7 mm 5/75 (6.7) 7/35 (20.0) 12/110 (10.9)
Total NA NA 203/1455 (14.0) 157/666 (23.6) 360/2121 (17.0)
NA = not applicable; NR = not reported.
* The rebleeding rate is the percentage derived by dividing the number of patients with a rebleed by the total 
number of patients.
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rebleeding of 2.32 (95% CI 1.77–3.04; p=0.00) and an OR of 2.56 (95% CI 1.62–4.06; p=0.00) 
for a fixed- and a random-effect model, respectively (Figure 5.2 upper). The results were 
subject to heterogeneity, which was determined by the I2 statistic to be 60%, indicating 
that the random-effect the results (Figure 5.2 lower). The funnel plot gave no indication 
of publication bias, but the findings are of limited value because of the small number of 
studies considered (Figure 5.3). The Egger regression test revealed an intercept of 2.3 with 
a 2-tailed p-value of 0.22, and it was accordingly not statistically significant. Five of the 7 
studies reported data on age; 4 studies provided age-adjusted results and identified a persistent 
relationship between size and the risk of rebleeding 10, 19, 28, 37. The presence of hypertension 
was reported in 2 studies and was more prevalent in patients with rebleeding in 1 of these 
Figure 5.2 Forest plots showing results of the meta-analysis of studies reporting rebleeding risk of large 
versus small aneurysms (upper) and sensitivity analysis (lower). 
The squares indicate the mean, the whiskers indicate the 95% CI, and the diamonds indicate the pooled 
estimate (the width of the diamond represents the 95% CI).
Model Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit Z-Value p-Value
Kassel & Torner, 1983 1.039 0.603 1.792 0.138 0.890
Pare et al., 1992 7.102 1.532 32.922 2.505 0.012
Machiel Plezier et al., 2006 2.430 1.191 4.956 2.441 0.015
Inagawa, 2010 2.297 1.325 3.981 2.962 0.003
Guo et al., 2011 4.154 2.301 7.502 4.723 0.000
Shiue et al., 2011 2.520 1.019 6.234 2.000 0.045
Wu  et al., 2012 4.333 1.243 15.104 2.302 0.021
Fixed 2.319 1.772 3.036 6.123 0.000
Random 2.562 1.619 4.056 4.015 0.000
0.01 0.1 1 10 100
Favours small aneurysms Favours large aneurysms
Study name Cumulative statistics Cumulative odds ratio (95% CI) 
Lower Upper 
Point limit limit Z-Value p-Value
Kassel & Torner, 1983 1.039 0.603 1.792 0.138 0.890
Pare et al., 1992 2.364 0.367 15.237 0.905 0.366
Machiel Plezier et al., 2006 2.130 0.849 5.342 1.612 0.107
Inagawa, 2010 2.069 1.130 3.790 2.354 0.019
Guo et al., 2011 2.457 1.380 4.376 3.054 0.002
Shiue et al., 2011 2.441 1.493 3.992 3.558 0.000
Wu et al., 2012 2.562 1.619 4.056 4.015 0.000
2.562   1.619 4.056 4.015 0.000
0.01 0.1 1 10 100
Favours small aneurysms Favours large aneurysms
Model
Random
A Meta-Analysis: rebleed risk in large vs small aneurysms 
B Sensitivity-Analysis: rebleed risk in large vs small aneurysms 
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studies 10, 19. Location (anterior vs posterior circulation) was reported in 5 studies, while in 
4 there was no difference in the rebleeding rate 10, 19, 33, 37, 41. One study identified a lower risk 
of rebleeding associated with posterior circulation aneurysms 37. These findings provide 
insufficient evidence to relate hypertension and/or location of the aneurysm with the 
rebleeding rate. 
Only a single study evaluated the risk of rebleeding over time dichotomized for size; the authors 
found a difference of rebleeding rate within 24 hours that persisted for 3 days after the initial 
hemorrhage 28. They reported a hazard ratio for large aneurysm of 2.4 (95% CI 1.2–4.5). In 
another study, median time to aneurysm obliteration did not differ between rebleeding and 
non-rebleeding groups but was not stratified according to lesion size 3.
The use of antifibrinolytic agents was reported only by 1 study; the investigators included 
patients from 1996 to 2011, and from 2003 on, they used, on a routine basis, aminocaproic 
acid for all patients before aneurysm clipping or coiling 27.
Conflicting results have been reported regarding the effect of clinical grade on the risk of 
rebleeding. Six studies evaluated Hunt and Hess grade as a factor in relation to rebleeding. 
One study matched for Hunt and Hess grade found a significant difference in aneurysm 
size in those with rebleeding versus those without rebleeding 27. Two studies reported no 
significant association between Hunt and Hess grade and rebleeding risk 32, 40. The authors 
of one study concluded that the larger the aneurysm, the worse was the World Federation 
Figure 5.3 Funnel plot. 
The points correspond to the treatment effects from individual studies, the diagonal lines show the expected 
95% confidence intervals around the summary estimate. Odds ratios are plotted on a logarithmic scale.
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of Neurosurgical Societies grade, but did not report it as a independent risk factor 14. Two 
studies found Hunt and Hess grade to be a statistically significant independent risk factor 
for rebleeding (ORs 2.5 and 4.9) 5, 7. Clinical grade at admission is a possible independent 
risk factor for rebleeding.
Discussion
The findings of this meta-analysis show that aneurysm size is an important determinant 
of aneurysmal rebleeding. Age and location are unlikely to be confounding factors. The 
presence of hypertension was insufficiently registered to determine the role of possible 
confounding effects. To reduce rebleeding rates, patients with large aneurysms should, 
when feasible, undergo acute treatment rather than ultra-early treatment, despite possible 
logistical issues. Additionally, if patients are referred from other centers, or if the diagnosis 
is delayed, those with large aneurysms still require urgent treatment because it has been 
shown that the effect size of this association might persist for up to 72 hours after the initial 
bleed 28. An increased risk is seen even within 24 or 48 hours, the time window in which 
most aneurysm are currently treated 25. 
The results of this analysis for ruptured aneurysms correspond with those of the ISUIA 
study, in which the primary bleeding risk was greater for individuals with larger unruptured 
aneurysms 40. 
The present research has several limitations. First, there is a potential for publication bias; 
studies showing no association between aneurysm diameter and rebleeding rate are less likely to 
be published. The estimated effect size in this meta-analysis could therefore be overestimated. 
Second, the studies considered did not include data from patients who had died before 
hospital admission, and this rate would be estimated to be as high as 15% 26. Rebleeding rates 
during transfer to the hospital were also included and may be as high as 24% 10. Moreover, 
the average time to hospital admission varied considerably after the initial aSAH. Only one 
study reported median time to aneurysm repair and aneurysm rebleeding 10. The research by 
Machiel Pleizier et al. revealed that there is no significant difference between small and large 
aneurysms when it comes to the risk of rebleeding 72 hours after the initial SAH 28. Third, only 
one study reported the use of aminocaproic acid 27. Although antifibrinolytic therapy does 
not improve survival or the chance of being independent in activities of daily living, it does 
reduce the risk of rebleeding by approximately 35%, as indicated in a recent Cochrane review 1. 
Therefore, it is an important factor in rebleeding rate; unfortunately, the published studies did 
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not provide data with which to evaluate the effects of both size and antifibrinolytic therapy 
together. Fourth, the cutoff for aneurysm size at 10 mm is artificial and chosen based on the 
categories set out in the published literature. Fifth, even if rebleeding is prevented in patients 
with large aneurysms, there is still a substantial rate of rebleeding events (14.0%) in cases 
involving small aneurysms. Only the acute treatment of all patients is optimal for prevention of 
rebleeding 28.
Hypothetically, acute treatment could be associated with additional treatment risks like 
increased intraoperative rupture due to the newly formed instable thrombus. However, 
for treatment within 24 hours, it has been shown that this timeframe was associated with 
improved clinical outcomes, although the benefit was more pronounced for coiling than 
clipping 34. Moreover, it is unlikely that the risks of acute treatment will accrue in such a way 
that they outweigh the very high morbidity and mortality rates associated with rebleeding.
Conclusions
This meta-analysis showed that aneurysm size is an important risk factor for aneurysmal 
rebleeding and should be used in the clinical risk assessment of individual patients. Our 
results confirmed the current guidelines and stressed the importance of acute treatment 
for large ruptured aneurysms.
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Abstract
Background
Initiation of external cerebrospinal fluid (CSF) drainage has been associated with a significant 
increase in rebleeding probability after aneurysmal subarachnoid hemorrhage (aSAH). 
However, the implications for acute management are uncertain. The purpose of this study 
was to evaluate the role of the amount of drained CSF on aneurysmal rebleeding.
Methods
Consecutive patients with aSAH were analyzed retrospec tively. Radiologically confirmed 
cases of aneurysmal in-hospital rebleeding were identified and predictor variables for 
rebleeding were retrieved from hospital records. Clinical predictors were identified through 
multivariate analysis and logistic regression analysis was performed to ascertain the cutoff 
value for the rebleeding probability. 
Results
The study included 194 patients. Eighteen cases (9.2%) of in-hospital rebleeding could be 
identified. By multivariate analysis, in-hospital rebleeding was associated with initiation 
of CSF drainage (p=0.001) and CSF drainage volume (63 ml [55–69] vs. 25 ml [10–35] 
p<0.001). Logistic regression shows that 58 ml CSF drainage within 6 hours results in a 50% 
rebleeding probability. The relative risk for rebleeding after drainage of more than 60 ml in 
6 hours is 5.4 times greater as compared to patients with less CSF drainage (RR 5.403, 95% 
CI 2.481–11.767; p<0.001, NNH 1.687). 
Conclusion
Volume of CSF drainage was highly correlated with the probability of in-hospital aneurysmal 
rebleeding. These findings suggest that the rebleeding probability can be affected in acute 
management should the placement of an external ventricular catheter be necessary. This 
necessitates meticulous control of the amount of drained CSF and the development of a 
definite treatment protocol for this group of patients.
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Background
The incidence of aneurysmal subarachnoid hemorrhage (aSAH) ranges from 2 to 23 cases 
per 100,000 and is associated with significant morbidity and mortality 1, 2. Of all aSAH 
patients, an estimated 5.8–22% will suffer from aneurysmal rebleeding 3-7. These events 
usually occur within the first 24 hours of the primary bleed and have an associated mortality 
rate of 50–60% 5, 7. As rebleeding significantly impairs prognosis its prevention is one of the 
primary goals of acute management 5, 6. 
However, concurrent challenges such as acute hydrocephalus or the need for invasive 
neuromonitoring may demand the use of an external ventricular drain (EVD), which 
leads to changes in transmural pressure across the aneurysm wall. Changes in transmural 
pressure have long been regarded as a possible cause for rebleeding and studies have shown 
that indeed the initiation of external cerebrospinal fluid (CSF) drainage is associated with 
a significant increase in rebleeding probability 3, 8, 9. 
In clinical practice, it is still unclear whether this intervention complicates acute management 
and what consequences for patients with aSAH should be drawn. In this context, we aimed 
to identify risk factors for in-hospital rebleeding before aneurysm occlusion and focus on 
the effect of CSF drainage on the incidence of aneurysmal rebleeding.
Methods
Study population
We conducted a retrospective study of 194 consecutive patients with radiologically confirmed 
aSAH admitted to the Heinrich-Heine University Medical Centre between May 2012 and 
January 2016. The ethics committee of the Heinrich-Heine University Medical Centre 
approved this study (study number 5361).
Treatment protocol
A standardized treatment protocol is applied to all patients admitted to our center with a 
SAH as described elsewhere 10, 11. All patients undergo immediate computed tomographic 
angiography and perfusion computed tomography (PCT) upon admission. Patients are 
monitored on our neuro-intensive care unit (NICU) under a minimal touch regime until 
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aneurysm closure. The systolic blood pressure (SBP) is lowered not to exceed 140 mmHg. 
Antifibrinolytic agents are only applied when definite aneurysm closure cannot be achieved 
within 36 hours.
Management of EVD and CSF drainage
In patients with a Glasgow Coma Scale below 13 invasive neuromonitoring with insertion 
of an intraventricular catheter is initiated. All patients adhered to a standardized drainage 
protocol. The intracranial pressure (ICP) threshold is set at 18 mmHg. ICP is monitored 
continuously and CSF is drained in case of sustained elevation of ICP above the set limit. 
When the ICP exceeded 18 mmHg for a period >15 minutes, the EVD was opened at a 
hydraulic pressure level of 18 mmHg. Drainage of CSF was halted immediately when ICP 
dropped to 18 mmHg and none of the patients were treated under a continuous hydraulic 
drainage paradigm. The drained volume of CSF is documented hourly. 
Data collection and definitions
For all 194 included patients epidemiologic, clinical and radiological data were collected. 
From this study population the number of rebleeding events was identified. Aneurysmal 
rebleeding was defined as CT-confirmed episodes of in-hospital rebleeding in which imaging 
was prompted by any neurological deterioration, or otherwise clinical suspicious events in 
comatose patients; like bradycardia, sudden rise in blood pressure or the appearance of fresh 
blood through ventricular drainage 12. The amount and intensity of blood was compared 
to that on the preceding CT. Rebleeding before hospitalization was registered, events after 
aneurysmal obliteration were not included. For further analysis, only patients with CSF 
drainage initiated at least 6 hours before aneurysm closure were included to allow for uniform 
analysis of the retrospective data (Figure 6.1). 117 patients were excluded from secondary 
analysis because CSF drainage had been started after aneurysm closure (n=45), or no CSF 
drainage was initiated (n=72). Another 12 patients were excluded because of incomplete 
data or variable duration of CSF drainage. In total, 65 patients (21 Men, [32.3%], mean age 
58.6 ± 12.6 years) were included for further analysis (Figure 6.1). For the included patients 
we registered the volume of CSF drainage at 6, 12 and 24 hours before aneurysm closure. 
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Statistical analysis
Categorical data are presented as counts and percentages and continuous variables as mean 
with standard deviation (SD) or median with interquartile range (IQR) depending on the 
normality of data. 
We performed univariate analysis of all clinically important covariates (see Table 6.1). For 
categorical data (Fisher-Grade, WFNS scale) we discriminated between a poor grade and a 
good grade due to the strong dichotomy: WFNS ≤3, ≥4, Fisher score <4, =4. Variables were 
tested for an association with rebleeding with the Fisher exact test (grouped data), t-test 
(for continuous normally distributed variables), or the Mann-Whitney test (for continuous, 
non-normally distributed variables). Multivariate analysis was performed to identify factors 
associated with aneurysmal rebleeding. We considered a 2-tailed p-value of 0.05 statistically 
significant. Binary logistic regression analysis was performed to ascertain the cutoff point 
from the variable identified through multivariate analysis for the prediction of rebleeding. 
For the patients with a volume of CSF drainage above the 50%-probability line in the binary 
logistic regression analysis we calculated a relative risk with 95% confidence interval (CI) and 
Figure 6.1 Flowchart demonstrating the selection process for the study.
194 patients with aneurysmal subarachnoid hermorrhage
77 patients received external ventricular drainage before aneurysm 
closure
65 patients included in the analysis
117 excluded
45 patients received external ventricular drainage 
after aneurysm closure
72 patients did not receive any CSF drainage
12 excluded
no adequate documentation or variable duration of 
CSF drainage
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Table 6.1 Univariate und multivariate factors related to a rebleeding event in 194 aneurysm patients
Number of patients (%)
Univariate 
analysis
Mulitvariate
analysis
All patients Rebleeding Non-rebleeding p-value p-value
Total 194 (100%) 26 (13.4 %) 168 (86.6%) … …
Female 116 (59.8%) 16 (61.5%) 100 (59.5%) … …
Male 78 (40.2%) 10 (38.5%) 68 (40.5%) … …
Age (mean ± SD) 55.6 ± 12.4 60.3 ± 12.4 54.8 ± 12.3 … …
WFNS-grade on admission
1 61 (31.4%) 0 (0%) 61 (36.3%) … …
2 27 (13.9%) 1 (3.8%) 26 (15.4%) … …
3 16 (8.2%) 5 (19.2%) 11 (6.5%) … …
4 31 (16.0%) 3 (11.5%) 28 (16.7%) <0.001 0.010
5 59 (30.4%) 17 (65.4%) 42 (25%) … …
Fisher grade on admission
1 10 (5.2%) 0 (0%) 10 (6%) … …
2 7 (3.6%) 0 (0%) 7 (4.2%) … …
3 50 (25.8%) 1 (3.8%) 49 (29.2%) … …
4 127 (65.5%) 25 (96.2%) 102 (60.7%) <0.001 0.144
Aneurysm size§ 0.059 0.095 
0 – <5 mm 69 (35.6%) 4 (15.4%) 65 (38.7%) … …
5 – <10 mm 99 (51%) 16 (61.5%) 83 (49.4%) … …
10 – <15 mm 20 (10.3%) 5 (19.2%) 15 (8.9%) … …
15 – <20 mm 2 (1%) 1 (3.8%) 1 (0.6%) … …
>20 mm 4 (2.1%) 0 (0%) 4 (2.4%) … …
Aneurysm location 0.344 …
Anterior 134 (69.1%) 17 (65.4%) 117 (69.6% … …
Posterior 60 (30.9%) 9 (34.6%) 51 (30.4%) … …
External CSF drainage before aneurysm closure <0.001 0.001 
Yes 77 (39.7%) 17 (94.4%) 60 (34.1%) … …
No 117 (60.3%) 1  (5.6%) 116 (65.9%) … …
* Values are presented as number (%), unless otherwise indicated.
§ Missing data: Aneurysm size N=1 (0.5%).
number needed to harm (NNH); to cause one rebleeding due to high volume CSF drainage. 
Correlation (R) between individual variables was calculated using pearson’s product-moment 
correlation. All statistical analysis was performed using the R statistical computing package, 
R version 3.2.2 as released on 2015-08-14 (https://r-project.org/).
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Results
Patient demographics and rebleeding incidence
The characteristics of the study population are listed in Table 6.1. Pretreatment rebleeding 
was radiologically confirmed in 26 of 194 patients (13.4%). These 26 patients had a total of 
28 rebleeding events. Ten of these patients had a rebleeding event during transport from 
the referring hospital to our clinic (5.2%). Two patients had both an out-of-hospital and in-
hospital rebleeding event, resulting in a 9.3% (n=18) in-hospital rebleeding rate. The time 
distribution of patients with in-hospital rebleeding is depicted in Figure 6.2.  
Figure 6.2 Time interval between admission and in-hospital aneurysmal rebleeding.
Interventions 
The median time to aneurysm repair in all patients was 15 hours (IQR 6–23) after admission; 
the median time for EVD placement was three hours (IQR 2–5). From the 77 patients 
that received CSF drainage before aneurysm closure, 17 patients (22.1%) suffered from 
aneurysmal rebleeding. Two patients had aneurysmal rebleeding shortly after initiation of 
CSF drainage and no documented amount of drained CSF volume could be retrieved from 
the charts. There was no difference in duration of CSF-drainage between the rebleeding 
and non-rebleeding group (17 hrs. [IQR 7.5–21.5 hours] vs. 14 hrs. [IQR 8.5–21 hours], 
p=0.58). In total, 65 patients (33.5%) underwent CSF drainage over a course of at least 6 
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hours. Characteristics of these patients are listed in Table 6.2. Rebleeding occurred in 15 
of these patients (23.0%). In 25 cases (12.9%), CSF drainage continued over a course of 24 
hours and four of the 15 rebleeding events occurred after this timeframe. Of these four 
patients, aneurysm closure was delayed because of cardiac or respiratory complications 
(three patients), or logistic reasons (one patient). None of the patients was treated with 
antifibrinolytic agents.
Risk factors for aneurysmal rebleeding
In multivariate regression analysis the independent predictors for aneurysmal rebleeding 
were WFNS grade ≥4 (p=0.010) and the initiation of CSF drainage before aneurysm closure 
(p=0.001) (Table 6.1). Factors related to aneurysmal rebleeding in patients with EVD 
before aneurysm closure are presented in Table 6.2. The rebleeding-positive group had a 
significantly higher volume of CSF drainage before aneurysmal rebleeding compared to the 
rebleeding negative group (Figure 6.3; 63 ml [55–69] vs. 25 ml [10–35], p<0.001). In logistic 
regression analysis, a drained volume of 58 ml within 6 hours was identified as cutoff value 
(CV); the lower range of the 95% CI establishes the 50% probability line at 49 ml (Figure 
Table 6.2 Univariate and multivariate factors related to a rebleeding event in 65 patients with EVD before 
aneurysm closure
Rebleeding
positive
Rebleeding
negative
Univariate 
analysis
Multivariate
analysis
n=15 n=50 p-value p-value
WFNS grade ≥4 12 (80.0%) 34 (68.0%) 0.522 …
Fisher grade >3 14 (93.3%) 41 (82.0%) 0.431 …
Aneurysm diameter >10 mm 9 (60.0%) 8 (16.0%) 0.02 0.081
Aneurysm location
Anterior 10 (67.7%) 30 (60.0%) 0.767 …
Posterior 5 (33.0%) 20 (40.0%)
Amount of CSF drainage in 6 hours, ml [IQR] 63 [55–69] 25 [10–35]§ <0.001 <0.001
Time of EVD insertion after admission, 
hours [IQR]
2 [1–2.5] 3 [2–6] 0.390 …
Thrombocytopenia 5 (33.3%) 0 (0.0%) <0.001 0.993
* Values are presented as number (%), median values are presented with IQR.
§ Missing data: CSF drainage in 6 hours in N=2 (3%).
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6.4). At 12 hours after EVD insertion the effect remained statistically significant (CV 122 
ml, lower 95% CI 98.5 ml; p<0.001). However, the effect was lost after 24 hours as patients 
were excluded from further analysis due to aneurysm closure (p=0.062). The relative risk 
for rebleeding after drainage of more than 60ml in 6 hours is 5.4 times greater as compared 
to patients with less CSF drainage (RR 5.403, 95% CI 2.481–11.767; p<0.001, NNH 1.687). 
Independent predictors for a high volume of CSF drainage were aneurysmal diameter (R: 
0.301, 95% CI 0.058–0.511; p=0.016) and WFNS grade (R: 0.263, 95% CI 0.016–0.479; 
p=0.038) (Table 6.3). 
Figure 6.3 Box plot visualizing the difference in CSF-drainage between the rebleeding and non-rebleeding 
group.
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We did not find a significant difference in maximal SBP during admission between the 
rebleeding and the non-rebleeding group (152 mmHg ± 24 vs. 150 mmHg ± 20, p=0.737), 
nor was there a difference with the maximum SBP within the 30 minutes before aneurysmal 
rebleeding (126 mmHg ± 17 vs. 150 mmHg ± 20). We also did not observe more SBP spikes 
between the rebleeding and the non rebleeding group (above 140 mmHg p=1.000, or 160 
mmHg p=0.740). There were no significant differences in international normalized ratio 
(INR 1.07±0.07 vs. 1.04±0.06, p=0.099), partial thromboplastin time (PTT 23.3±3.6 vs. 
25.9±11.4, p=0.388), anti platelet therapy (p=0.153) or oral anticoagulation (p=0.381). The 
absolute thrombocyte count did not differ between the rebleeding (222 x1000/µl ±101) and 
non-rebleeding group (226 x1000/µl ±56, p=0.869). Five patients fulfilled the criterium for 
thrombocytopenia (thrombocyte count below 150 x1000/µl) and all belonged to the rebleeding 
Figure 6.4 Graph of the logistic regression for the identification of the rebleeding probability. The right 
(blue) and left (green) vertical lines represent the cutoff value and the lower range of its 95% CI, respectively.
Table 6.3 Independent predictive value for amount of CSF drainage
Correlation 95% CI p-value
WFNS grade 0.263 0.016–0.479 0.038
Fisher grade 0.114 -0.138–0.352 0.374
Aneurysm diameter 0.301 0.058–0.511 0.016
Aneurysm location 0.182 -0.073–0.411 0.091
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group (p<0.001). When presence of thrombocytopenia was included in the multivariate 
analysis it lost significance due to the strong effect of CSF drainage (p=0.993) (Table 6.2).
Discussion
This study revealed some novel issues about management of aSAH before aneurysm 
closure. First, initiation of external ventricular CSF drainage is independently associated 
with pretreatment rebleeding. Second, the amount of CSF volume drained is independently 
correlated to the rebleeding probability. 
The initiation of CSF drainage is, among other factors such as clinical condition, hypertension, 
aneurysm size and amount of subarachnoid blood, an independent risk factor for a rebleeding 
event after aSAH 3-5, 7, 13-16. Moreover, its deleterious effect during aneurysmal re-rupture 
suggested CSF drainage should be avoided during recurrent hemorrhages 17. 
However, the use of an EVD remains an undisputed and pertinent tool to treat acute 
hydrocephalus and continuous CSF drainage has also been advocated in the acute phase after 
aSAH to reduce the risk of ischemic complications 18, 19. Despite this controversy, thresholds 
for the volume of CSF drainage remain undefined even though there have been multiple 
reports on the adverse effects of early CSF drainage and accidental over-drainage on the 
incidence of aneurysmal rebleeding within the first 24 hours, underlining the need for CSF 
drainage guidelines with defined thresholds 3, 14. This volume mediated effect constitutes 
one of the most important predictors for rebleeding as demonstrated in our cohort. A 
volume of drained CSF above 60 ml within the first 6 hours increases the rebleeding risk 
significantly and should be avoided. In this respect, automated intracranial pressure- and 
volume-controlled CSF drainage systems might reduce the risk of rebleeding in these patients. 
Interestingly, although insertion of an EVD contributes to the rebleeding risk, timing of EVD 
placement and duration of monitoring and CSF drainage does not (Table 6.2).
Both premorbid hypertension and hypertension (HT) upon admission are well known risk 
factors and associated with increased severity of the initial bleeding event and represents a 
significant risk factor for aneurysm rebleeding 16, 20. Though HT upon and during admission 
was assessed, we did not include premorbid hypertension in our model. This might have 
influenced our results because of its significant effect in other reports. In our study, patients 
with thrombocytopenia are at increased risk of aneurysmal rebleeding. However this did 
not improve the validity of risk assessment compared to CSF drainage volume alone. The 
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application of antifibrinolytic drugs prior to EVD placement in patients requiring treatment 
for acute hydrocephalus should be discussed as this medication effectively reduces the 
incidence of rebleeding 21. However, the benefits of antifibrinolytic agents are still inconclusive 
due to a significantly higher rate of delayed cerebral ischemia and the failure of these agents 
to improve overall survival and functional outcome 21. Its effectivity in this selected situation 
therefore remains highly speculative. Recent publications show that aneurysm closure 
within 24 hours after ictus results in a lower rebleeding rate and improves clinical outcome 
22. However, the median time to aneurysm closure in our population was significantly lower 
than 24 hours. Aneurysm closure on an emergency basis would be an alternative strategy 
in order to reduce rebleeding 23. 
Limitations of this preliminary study are those that are generally associated with the 
retrospective analysis of small patient cohorts. As a result, we were unable to include patients 
with short periods of CSF drainage and exact amounts of CSF volume prior to rebleeding 
could not be determined. We realize that the cutoff of CSF drainage over a 6-hour period is 
arbitrary and it was chosen to allow for uniform analysis between patients. Two rebleeding 
patients were excluded because of this reason and this might affect our results. Also, as WFNS 
grade and aneurysm size were independent predictors for a high volume of CSF drainage, 
it is possible that these factors were driving the rebleeding events as these parameters have 
been linked to aneurysmal rebleeding in previous studies 3, 15.  
Moreover, our treatment protocol uses an intermitted drainage system and is likely to result 
in greater drops in ICP. As no continuous ICP values were available, we could not determine 
whether absolute drops in ICP play a role in the etiology of aneurysmal rebleeding. Finally, 
it is possible that our study underestimates the incidence of early rebleeding. Although 
the focus of this study does not lie at pre-admission rebleeding, patients in poor clinical 
condition might have had a rebleeding event without clear clinical signs, but it is unlikely 
that this would go unnoticed under invasive neuromonitoring. 
Despite these limitations, we were able to demonstrate a threshold for CSF drainage as one 
of the paramount contributors to aneurysm rebleeding and identify a group of patients in 
need for a yet undefined but much-needed treatment protocol. We believe that the risk for 
early rebleeding can be affected by an adequate treatment strategy and thus the protocol 
for a prospective trial to evaluate the role of controlled automated CSF drainage, the use of 
antifibrinolytic medication and ultra-early aneurysm closure is currently under development. 
Begin of this study is planned for the near future.
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Conclusion
The most significant factor for in-hospital rebleeding from an unsecured cerebral aneurysm 
was initiation of CSF drainage and the volume of drained CSF. This necessitates meticulous 
control of the amount of drained CSF in patients where drainage is needed due to acute 
hydrocephalus. Development of a definite treatment protocol for these patients is mandatory. 
Chapter_5_Jasper.indd   109 8-7-2018   08:04:42
Chapter 6
110
References 
1.  Ingall T, Asplund K, Mahonen M, Bonita R. A multinational comparison of subarachnoid hemorrhage 
epidemiology in the who monica stroke study. Stroke. 2000;31:1054-1061
2. Inagawa T. Trends in incidence and case fatality rates of aneurysmal subarachnoid hemorrhage in izumo 
city, japan, between 1980-1989 and 1990-1998. Stroke. 2001;32:1499-1507
3. van Donkelaar CE, Bakker NA, Veeger NJ, Uyttenboogaart M, Metzemaekers JD, Luijckx GJ, et al. Predictive 
factors for rebleeding after aneurysmal subarachnoid hemorrhage: Rebleeding aneurysmal subarachnoid 
hemorrhage study. Stroke. 2015;46:2100-2106
4. Guo LM, Zhou HY, Xu JW, Wang Y, Qiu YM, Jiang JY. Risk factors related to aneurysmal rebleeding. World 
Neurosurg. 2011;76:292-298; discussion 253-294
5. Ohkuma H, Tsurutani H, Suzuki S. Incidence and significance of early aneurysmal rebleeding before 
neurosurgical or neurological management. Stroke. 2001;32:1176-1180
6. Fujii Y, Takeuchi S, Sasaki O, Minakawa T, Koike T, Tanaka R. Ultra-early rebleeding in spontaneous 
subarachnoid hemorrhage. J Neurosurg. 1996;84:35-42
7. Larsen CC, Astrup J. Rebleeding after aneurysmal subarachnoid hemorrhage: A literature review. World 
Neurosurg. 2013;79:307-312
8. Hasan D, Vermeulen M, Wijdicks EF, Hijdra A, van Gijn J. Management problems in acute hydrocephalus 
after subarachnoid hemorrhage. Stroke. 1989;20:747-753
9. Pare L, Delfino R, Leblanc R. The relationship of ventricular drainage to aneurysmal rebleeding. J Neurosurg. 
1992;76:422-427
10. Connolly ES, Jr., Rabinstein AA, Carhuapoma JR, Derdeyn CP, Dion J, Higashida RT, et al. Guidelines for 
the management of aneurysmal subarachnoid hemorrhage: A guideline for healthcare professionals from 
the american heart association/american stroke association. Stroke. 2012;43:1711-1737
11. Steiner T, Juvela S, Unterberg A, Jung C, Forsting M, Rinkel G, et al. European stroke organization guidelines 
for the management of intracranial aneurysms and subarachnoid haemorrhage. Cerebrovasc Dis. 2013;35:93-
112
12. Beck J, Raabe A, Szelenyi A, Berkefeld J, Gerlach R, Setzer M, et al. Sentinel headache and the risk of 
rebleeding after aneurysmal subarachnoid hemorrhage. Stroke. 2006;37:2733-2737
13. Naidech AM, Janjua N, Kreiter KT, Ostapkovich ND, Fitzsimmons BF, Parra A, et al. Predictors and impact 
of aneurysm rebleeding after subarachnoid hemorrhage. Arch Neurol. 2005;62:410-416
14. Ruijs AC, Dirven CM, Algra A, Beijer I, Vandertop WP, Rinkel G. The risk of rebleeding after external lumbar 
drainage in patients with untreated ruptured cerebral aneurysms. Acta Neurochir (Wien). 2005;147:1157-
1161; discussion 1161-1152
15. Boogaarts HD, van Lieshout JH, van Amerongen MJ, de Vries J, Verbeek AL, Grotenhuis JA, et al. Aneurysm 
diameter as a risk factor for pretreatment rebleeding: A meta-analysis. J Neurosurg. 2015;122:921-928
16. De Marchis GM, Lantigua H, Schmidt JM, Lord AS, Velander AJ, Fernandez A, et al. Impact of premorbid 
hypertension on haemorrhage severity and aneurysm rebleeding risk after subarachnoid haemorrhage. J 
Neurol Neurosurg Psychiatry. 2014;85:56-59
Chapter_5_Jasper.indd   110 8-7-2018   08:04:42
111
Cerebrospinal fluid drainage and prevention of rebleeding
6
17. Voldby B, Enevoldsen EM. Intracranial pressure changes following aneurysm rupture. Part 3: Recurrent 
hemorrhage. J Neurosurg. 1982;56:784-789
18. Klimo P, Jr., Kestle JR, MacDonald JD, Schmidt RH. Marked reduction of cerebral vasospasm with lumbar 
drainage of cerebrospinal fluid after subarachnoid hemorrhage. J Neurosurg. 2004;100:215-224
19. Park S, Yang N, Seo E. The effectiveness of lumbar cerebrospinal fluid drainage to reduce the cerebral 
vasospasm after surgical clipping for aneurysmal subarachnoid hemorrhage. J Korean Neurosurg Soc. 2015; 
57:167-173
20. Solanki C, Pandey P, Rao KV. Predictors of aneurysmal rebleed before definitive surgical or endovascular 
management. Acta Neurochir (Wien). 2016;158:1037-1044
21. Baharoglu MI, Germans MR, Rinkel GJ, Algra A, Vermeulen M, van Gijn J, et al. Antifibrinolytic therapy 
for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2013:CD001245
22. Phillips TJ, Dowling RJ, Yan B, Laidlaw JD, Mitchell PJ. Does treatment of ruptured intracranial aneurysms 
within 24 hours improve clinical outcome? Stroke. 2011;42:1936-1945
23. Park J, Woo H, Kang DH, Kim YS, Kim MY, Shin IH, et al. Formal protocol for emergency treatment of 
ruptured intracranial aneurysms to reduce in-hospital rebleeding and improve clinical outcomes. J Neurosurg. 
2015;122:383-391
Chapter_5_Jasper.indd   111 8-7-2018   08:04:42
Chapter_5_Jasper.indd   112 8-7-2018   08:04:44
7Per-procedural aneurysm re-rupture 
in relation to timing of endovascular 
treatment and outcome
Jasper H. van Lieshout, Dagmar Verbaan, Rogier Donders, 
René van den Berg, W. Peter Vandertop, Catharina J.M. Klijn, 
Hans J. Steiger, Joost de Vries, Ronald H.M.A. Bartels, 
Kerim Beseoglu, Hieronymus D. Boogaarts
J Neurol Neurosurg Psychiatry. 2018 May 31. doi: 10.1136/jnnp-2018-318090
Chapter_6_Jasper.indd   113 9-7-2018   20:26:30
Chapter 7
114
Abstract
Background
Obliteration of ruptured intracranial aneurysms is initiated as soon as feasible to prevent 
rebleeding. A possible disadvantage of immediate aneurysm occlusion is a higher rate of 
procedural complications. We evaluated whether timing of endovascular aneurysm repair 
is a risk factor for per-procedural aneurysm re-rupture and if per-procedural aneurysm 
re-rupture has clinical impact.
Methods
All endovascularly treated, consecutive aneurysmal subarachnoid hemorrhage patients, 
treated at the Radboud University Medical Center (Nijmegen) and the Academic Medical 
Center (Amsterdam) between January 2012 and January 2016, were selected. Primary 
outcome measure was per-procedural aneurysm re-rupture. Secondary outcome was the 
modified Rankin Scale (mRS) score at six months’ follow-up. Predictors of rebleeding were 
assessed by univariate analysis, determinants for outcome by multivariate analysis. 
Results
Per-procedural aneurysm re-rupture occurred in 12 (2.5%) of 471 (mean age 57; 69.4% 
female) patients. In seven of these, coiling was performed within six hours after ictus, 
and this was a predictor for per-procedural aneurysm re-rupture (OR 9.0, 95% CI 2.8–29; 
p<0.001). Procedural re-rupture was related to poor outcome (mRS>2; aOR 7.0, 95% CI 
1.9–26; p=0.019, adjusted for age and clinical grade on admission) and increased case-fatality 
(aOR 7.8 95% CI 2.4–25; p<0.001). 
Conclusion
Endovascular coil embolization within six hours after ictus might expose patients to a 
higher probability of treatment-related aneurysm re-rupture. Early procedural aneurysm 
re-rupture also results in an increased case-fatality and a reduced chance of returning to 
daily life. Extra caution therefore, might be warranted if ultra-early aneurysm repair within 
six hours is contemplated. Alternatively, immediate endovascular intervention following the 
‘time-is-brain’ concept of ischemic stroke, might be considered.
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Background
The main aim in treatment of aneurysmal subarachnoid hemorrhage (aSAH) it securing the 
intracranial aneurysm to prevent spontaneous aneurysmal rebleeding, as this results in 60% 
case fatality 1. Some studies have found evidence for ultra-early treatment (<24 hours) or even 
emergency treatment of ruptured aneurysms in order to reduce aneurysmal rebleeding rates 
and improve clinical outcome 2, 3. The benefit has been suggested to be more pronounced for 
coiling than surgical clipping 2. Yet, inconsistent results and heterogeneity of most analyses 
result in a lack of evidence whether earlier endovascular treatment actually improves clinical 
outcome in patients with aSAH 4. Aneurysm obliteration within the first hours after initial 
rupture might also have an adverse effect as the fibrin net covering the aneurysm dome may 
be insufficiently strong to withstand coil placement and might therefore result in a higher 
chance of per-procedural aneurysm re-rupture 5-10. We aimed to establish whether timing 
of endovascular aneurysm repair is a risk factor for per-procedural aneurysm re-rupture 
and whether per-procedural rupture has any clinical impact.
Methods
Study population and inclusion
We included 471 consecutive patients with aSAH from two prospective observational databases, 
at the neurovascular centers from the Radboud University Medical Center (Radboudumc), 
Nijmegen, and the Academic Medical Center (AMC), Amsterdam, the Netherlands, between 
January 2012 and January 2016. The cohort contains no patients from the ultra-early tranexamic 
acid after subarachnoid hemorrhage (ULTRA) study 11. Only patients with a ruptured 
intracranial aneurysm who were treated by endovascular coil embolization were included 
(Figure 7.1). The institutional review boards approved this study. 
Data collection and organization of the register
Reporting of the study was according to the STROBE guidelines for observational studies, and 
adheres to the AHA journals’ implementation of the Transparency and Openness Promotion 
(TOP) guidelines 12. The Dutch national neurosurgical society (NVvN) has initiated a physician-
driven national outcome register for aSAH in order to improve quality of care (Quality Registry 
Neurosurgery, QRNS) in 2011. From the prospectively collected data patient characteristics 
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(age, sex), clinical (WFNS) and radiological (Fisher grade, aneurysm size) characteristics, 
treatment modality, complications and outcome were collected. Time of ictus was established 
by (hetero) anamnesis. Aneurysm size is a known risk factor for per-procedural complication; 
we defined small aneurysm size as ≤5 mm 6. The size of the ruptured aneurysm was determined 
by the largest diameter of the aneurysm.
Treatment protocol
A standardized treatment protocol was applied to all patients admitted with aSAH, as described 
elsewhere 13, 14. Some regional differences did exist. At Radboudumc, radiological imaging is 
evaluated and treatment decisions made by hybrid vascular neurosurgeons and in the AMC 
by interventional neuroradiologists and vascular neurosurgeons in consensus. For patients in 
poor clinical condition (WFNS grade 5), timing of treatment was variable and could have been 
postponed in individual cases. At the Radboudumc patients are monitored on the intensive 
care unit (ICU) prior to aneurysm closure, whereas in Amsterdam, patients are monitored on 
a specialized brain care unit, and only transferred to the ICU if monitoring or support of vital 
Figure 7.1 Flowchart.
Demonstration of the selection process for the study.
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functions is necessary. Until aneurysm closure, at Radboudumc blood pressure is lowered using 
administration of intravenous labetalol, in patients with a mean arterial pressure >110 mmHg 
and at the AMC in patients with a mean arterial pressure >135 mmHg. Antifibrinolytic agents 
are applied when definite aneurysm closure cannot be achieved within 36 hours (Radboudumc). 
Endovascular treatment
All endovascular treatments were performed under general anesthesia by experienced neuro-
interventional specialists, with at least five years of experience. Heparin (2500–3500 IE) was 
administered after adequate placement of the first coil (AMC), or at the start of the intervention 
(Radboudumc). Coiling was performed using a coaxial access. In the vast majority of patients, 
an Excelsior SL-10 microcatheter (Stryker Neurovascular) was used to catheterize the 
aneurysm. A multitude of micro-guidewires was used in combination with the micro-catheter, 
depending on personal preference of the interventionalists (Transed 14 or Synchro 14 from 
Stryker Neurovascular, Traxcess EX from Microvention or Avigo from Medtronic). Balloon 
catheters were only used in incidental cases with wide-neck aneurysms. For embolization, 
either Target coils (Stryker Neurovascular) or Micrus coils (Micrus Endovascular, Codman 
Neurovascular, Johnson & Johnson Co., DePuy Sunthes) were used. 
Definitions and outcome parameters
The primary outcome of this study was per-procedural aneurysm re-rupture during 
endovascular treatment. For per-procedural aneurysm re-rupture we used the previously 
proposed definition: aneurysmal re-rupture attributed to the use of endovascular devices, with 
extravascular effusion of contrast visible during digital subtraction angiography, regardless 
of hemodynamic changes 15, 16. Increase of subarachnoid blood on the CT-scan following the 
intervention was not sufficient for classification of a procedural re-rupture. Per-procedural 
re-rupture was distinguished from spontaneous aneurysmal rebleeding. Spontaneous 
aneurysmal rebleeding was defined as CT-confirmed episodes of pre-treatment rebleeding, 
in which imaging was prompted by any neurological deterioration, or otherwise clinically 
suspicious events in comatose patients such as bradycardia, sudden rise in blood pressure or 
the appearance of fresh blood through external ventricular drainage 17. 
The secondary outcome of the study was clinical outcome at six months after treatment as 
measured by the modified Rankin scale (mRS), as determined by a specialized nurse who had 
not been involved in the treatment. 
Chapter_6_Jasper.indd   117 9-7-2018   20:26:30
Chapter 7
118
Data analysis
Categorical data are presented as numbers (percentages) and continuous variables as mean 
± standard deviation (SD) or median with interquartile range (IQR) depending on the 
distribution. Categorical data (Fisher-Grade, WFNS and mRS) were dichotomized due to 
the small number of patients in the re-rupture group into Fisher score 1–3 and 4, good 
(WFNS 1–3) and poor clinical condition (WFNS 4–5), good (mRS ≤2) and poor (mRS >2) 
outcome 18. Per-procedural aneurysmal re-rupture was tested for an association with timing 
of aneurysm closure, age, sex, WFNS grade, Fisher grade and aneurysm size with the t-test 
or Fisher exact test as appropriate. Known major determinants of outcome (age, WFNS) and 
per-procedural aneurysm re-rupture were tested in a multivariate logistic regression model 19. 
The type I error was set at 0.05 and the tests were two-tailed. Patients with missing data or 
those lost to follow-up were excluded from the analysis (Table 7.1). All statistical analyses were 
performed using IBM SPSS Statistics version 22.0, release 22.0.0.1 for Windows.
Results
Incidence of procedural perforation and aneurysmal rebleeding
In total there were 471 patients (mean age 56.6; SD ± 13.1 years; 69.4% female) with aSAH. 
The remaining characteristics of the study population are listed in Table 7.1. Patient inclusion 
is depicted in Figure 7.1. The median time to aneurysm repair in all patients was 19 hours 
(IQR 32.5) after ictus. Spontaneous pretreatment aneurysmal rebleeding within the first six 
hours following ictus occurred in 18 (4.4%) of 405 patients. Per-procedural aneurysm re-
rupture occurred in 12 (2.5%) patients (Table 7.2), and were evenly distributed between the 
two centers. Nine (75.0%) of these 12 patients were treated during office hours (8:00 a.m. and 
6:00 p.m.). One of the patients (patient No. five) with a procedural aneurysm re-rupture also 
experienced a spontaneous aneurysmal re-bleeding prior to intervention.
All 12 procedural aneurysm re-ruptures were caused by perforation of the aneurysm by 
endovascular devices. In 11 patients perforations were caused by coils and in one patient by 
a microcatheter. Of 66 patients who were treated within six hours after ictus, seven (10.6%) 
had per-procedural aneurysm re-rupture. In the patients treated after six hours, five out of 405 
(1.2%) patients experienced a re-rupture. Figure 7.2 depicts the occurrence of per-procedural 
aneurysm re-rupture and spontaneous aneurysmal rebleeding in the interval between ictus 
and endovascular treatment (≤12 hours).  
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Table 7.1 Subarachnoid hemorrhage and aneurysm characteristics
Univariate 
analysis
All patients
n=471
Procedural 
re-rupture
n=12
No procedural 
re-rupture
n=459
p-value
…
Age (mean±SD) 56.6±13.1 65.3±12.6 56.3±13.1 p=0.025†
Female 327 (69.4%) 10 (83.3%) 317 (69.1%) p=0.001‡
WFNS grade on admission  >3 133 (28.2%) 4 (33.3%) 129 (28.1%) p=0.231‡
Fisher grade on admission  >3 302 (64.1%) 9 (75%) 293 (63.8%) p=0.203‡
Aneurysm diameter ≤5 mm 208 (44.2%) 4 (33.4%) 204 (44.4%) p=0.198‡
Time of treatment after ictus, hours
≤6 hours 66 (14%) 7 (58.3%) 59 (12.9%) p<0.001‡
≤24 hours 289 (61.4%) 10 (83.3%) 279 (60.1%) p=0.226‡
≤72 hours 387 (82.2%) 11 (91.7%) 376 (81.9%) p=0.546‡
*Incomplete data n=19 (4%). 
† T-test.
‡ Fisher exact test.
N = Number of patients.
Figure 7.2 Procedural aneurysm re-rupture and spontaneous aneurysmal rebleeding.
Number of patients with procedural aneurysm re-rupture and spontaneous aneurysmal rebleeding within 
the first twelve hours following ictus (in one hourly intervals).
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Risk factors for per-procedural re-rupture
Patients with per-procedural re-rupture were older and more often female (Table 7.1). 
Similarity between the per-procedural re-rupture and non-re-rupture group indicates 
that emergency endovascular embolization was not initiated by worse clinical status upon 
admission or increased incidence of pretreatment aneurysmal rebleeding. Factors related to 
per-procedural aneurysm re-rupture in patients with aSAH are presented in Table 7.1. In 
patients with per-procedural re-rupture time from ictus to treatment was shorter (5.5 hours, 
IQR 20.5) than in those without per-procedural re-rupture (19 hours, IQR 86.4; p=0.021). 
Heparin was antagonized by application of protamine sulfate and complete aneurysm 
obliteration was performed in all cases. None of the patients with procedural aneurysm re-
rupture were treated with balloon-assisted coiling. Univariate analysis identified the following 
predictors for procedural aneurysmal re-rupture: age (p=0.025), female gender (p=0.001) and 
endovascular treatment within six hours after subarachnoid hemorrhage (p<0.001) (Table 
7.1). The odds ratio (OR) of procedural aneurysmal re-rupture within six hours after ictus 
was 9.5; 95% CI 2.9–30.9; p<0.001.  
Clinical outcome
Information on clinical outcome six months after treatment was available for all 12 (100%) 
patients in the procedural re-rupture group and for 403 (87.8%) patients in the non-rerupture 
group (Table 7.3). Patients with procedural aneurysm rupture were more likely to remain 
dependent (mRS>3; adjusted odds ratio (aOR) 7.0, 95% CI 1.9–26; p=0.019) and risk increased 
case-fatality (aOR 7.8, 95% CI 2.4–25; p<0.001), both independent of age and clinical grade on 
admission (Table 7.3). Five of seven (71.4%) patients who had a per-procedural aneurysmal 
re-rupture within six hours after ictus died during the admission. Four (80%) of these deaths 
were directly related to the clinical deterioration following intervention. One of the five 
patients who had procedural aneurysm re-rupture beyond six hours after ictus died.
Procedural re-rupture versus spontaneous aneurysmal rebleeding
Patients who experienced spontaneous aneurysm rebleeding were more often of younger 
age and presented with higher clinical and radiological grades (WFNS and Fisher grade) 
when compared to those with procedural aneurysm re-rupture (Table 7.4). However, these 
parameters failed to reach statistical significance.
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Table 7.3 Patient outcome related to procedural aneurysm re-rupture
Univariate 
analysis
Multivariate 
analysis*
Outcome after 6 
months, cut-off
All patients
n=413
Procedural 
re-rupture
n=12
No procedural 
re-rupture
n=403 p-value p-value
mRS≤2 285 (69.0%) 3 (25%) 282 (70.0%) p=0.001 p=0.019
mRS=6 51 (12.3%) 6 (50%) 46 (11.4%) P<0.001 P<0.001
*Corrected for WFNS Grade and Age. 
mRS = modified Rankin Scale;  n = number of patients.
Table 7.4 Patient characteristics in the procedural re-rupture versus spontaneous rebleeding group
Univariate analysis 
Procedural re-
rupture
n=11*
Spontaneous 
rebleeding
n=36 p-value
Age (mean±SD) 65.4±13.2 57.9±12.7 p=0.108
WFNS grade on admission  >3 3 (27.3%) 15 (41.7%) p=0.280
Fisher grade on admission  >3 8 (72.7%) 32 (88.9%) p=0.133
Aneurysm diameter ≤5 mm 4 (36.4%) 13 (36.1%) p=0.870
* One patient was excluded because she suffered both spontaneous rebleeding and a procedural re-rupture.
n = number of patients.
Discussion
This study shows that emergency (< six hours) endovascular embolization after aneurysm 
rupture is associated with a higher percentage of per-procedural aneurysm re-rupture, even 
when performed by experienced neuro-endovascular specialists. Per-procedural perforation 
was also related to poor clinical outcome and case-fatality. 
In current clinical practice, treatment of ruptured intracranial aneurysm is initiated as 
soon as feasible, based on the hypothesis that early occlusion of the aneurysm reduces 
rebleeding rates and therefore, could improve patient outcome 13, 14. A recently published 
meta-analysis, which included 16 observational cohort studies, suggested that ultra-early 
endovascular treatment of ruptured aneurysms may result in improved clinical outcome 4. 
However, some of the included studies compared ultra-early treatment with any treatment, 
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including treatment delayed as long as beyond 72 hours, which may in part disparate results. 
The decision for treatment beyond 72 hours may have resulted from clinical or aneurysmal 
characteristics, which may have contributed to poor outcome in the group with late treatment. 
In the meta-analysis, comparison of the outcome after treatment within 24 hours and between 
24–72 hours showed no clinical benefit of early treatment 4. Adjusted analysis in one study 
even suggested that ultra-early treatment exposes patients to additional harm 4, 9, 20. Several 
explanations for the lack of effectiveness of aneurysm treatment <24 hours have been 
postulated. Since most rebleeding events take place within the first six hours, with a median 
interval of 180 minutes, it has been hypothesized that achieving aneurysm occlusion in order 
to prevent the rebleeding events would prove to be challenging within this time frame 1, 9, 21, 22. 
A significant part of our patients was treated within six hours after ictus, but displayed a 
high per-procedural re-rupture rate. Our results therefore, could provide an explanation as 
to why early endovascular treatment (within 24 hours) does not seem to result in a clinical 
benefit compared to later treatment (24–72 hours). An unstable thrombus during the early 
course of disease could render the aneurysm more vulnerable during early (< six hours) 
endovascular coiling. Not only is there an increased risk of perforation during coiling, the 
diagnostic angiography itself could bear an increased risk for aneurysmal re-rupture when 
performed within six hours 10.
Previous studies found that per-procedural aneurysm re-rupture does not lead to reduced 
clinical outcome or death 23. The discrepancy between our results and previous studies 
could be caused by the early phase of disease (< six hours) in which most of the events from 
our study took place. Early per-procedure aneurysm re-rupture could increase the clinical 
impact of these events by delaying recovery from early brain injury 9, 17.
Strengths of our study include the prospective design of two observational databases, 
representing a homogenous national setting, and its consistency with recommendations on 
observational studies 12. However, despite the collaboration between two referral centers, 
the number of patients with per-procedural aneurysm re-rupture was small. Due to the 
retrospective study design we could not analyse all potentially relevant factors, such as 
blood pressure on admission and during the procedure. Moreover, possible imprecision 
in determining time of ictus might have altered our findings. Finally, this study was 
observational, so conclusions cannot be drawn on the effects of timing of treatment.
Our results suggest that the spontaneous rebleeding group is younger and had higher 
WFNS and Fisher grade, but analyses did not reach statistical significance. Similar patient 
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characteristics between the two groups will complicate clinical decision-making. For 
patients at risk for spontaneous aneurysmal rebleeding, in whom it is logistically possible 
to perform emergency aneurysm occlusion, the clinical benefit of early repair might be 
offset by a higher rate of procedural aneurysm re-rupture (10.6%, within six hours). If the 
overall net effect of emergency aneurysm occlusion is to make up for the higher rate of 
procedural aneurysm re-rupture, it might be beneficial to regard aSAH as a neurological 
emergency analogous to ischemic stroke where the concept of ‘time-is-brain’ nowadays 
leads to immediate endovascular interventions with extremely short door-to-repair times.
Reversal of heparin anticoagulation and placement of a second microcatheter in the 
aneurysm to complete the embolization is suggested to limit the consequences, but could 
not prevent death in most cases from our cohort 16. 
Future efforts to reduce the higher probability of treatment-related aneurysm re-rupture 
might focus on new technical advances such as flow disruption with the Woven Endobridge 
(WEB)-devices, which can hypothetically decrease per-procedural re-rupture rates by 
reduced manipulation of the aneurysm dome. Timing of Heparin administration during 
the procedure, before or after placement of the first coil, may also influence outcome. 
The variation in results from previous studies concerning the timing of endovascular 
aneurysm closure justifies additional observational studies of early treatment. Based on 
the present data, the overall net effect of early endovascular aneurysm closure is unclear. 
Conclusion
Endovascular coil embolization within six hours after ictus might expose patients to a 
higher probability of treatment-related aneurysm re-rupture. Early procedural aneurysm 
re-rupture also results in an increased case-fatality and a reduced chance of returning to 
daily life. Extra caution therefore, might be warranted if ultra-early aneurysm repair within 
six hours is contemplated. Alternatively, immediate endovascular intervention following the 
‘time-is-brain’ concept of ischemic stroke, might be considered. 
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Summary
The factors involved in the immediate pathophysiological changes following aneurysmal 
subarachnoid hemorrhage (aSAH) have attracted significant scientific interest; however, 
a unifying theory has not yet been described (Chapter two). Several new concepts and 
mechanisms were described and investigated over the last two decades. Some are quite 
novel and their clinical value (e.g., microcirculatory dysfunction, capillary transit time 
heterogeneity, or cortical spreading inflammation) has yet to be evaluated in further studies. 
The clinical impacts of cortical spreading depolarization, depression and ischemia, and 
early brain injury (EBI) have been documented, while the role of angiographic vasospasms 
is increasingly being questioned. Furthermore, it remains unclear how these different 
pathophysiological mechanisms following aSAH are connected. As previously discussed, 
some of them may be causally connected or present themselves as epiphenomena of an 
associated process. If these mechanisms have no causal pathophysiological connection 
and are all individually evoked by the subarachnoid blood and its degradation, multiple 
treatment strategies are required to address the different pathophysiological mechanisms 
involved; however, if there is a causal connection between delayed cerebral ischemia (DCI) 
and EBI, future therapies should address EBI more specifically.
Comparing international incidence rates and life-style factors facilitates the testing of 
hypotheses regarding the causality of aSAH. Disease-specific incidence rates are often used 
to evaluate national healthcare programs or policy decisions. Studies from countries with 
exceptional incidence rates are sometimes disregarded because of the concerns regarding 
their external validity, however, with the exception of Nordic countries, detailed reports 
of nationwide aSAH incidence rates are largely unavailable for comparison 1, 2. The Nordic 
incidence rates have been considered outliers because smaller cross-sectional studies from 
other countries have reported very different rates of aSAH. Using a nationwide registry, we 
monitored the German population (80 million) during 321.2 million person-years of follow 
up, revealing that the incidence rates of aSAH are much more homogenous than previously 
reported (Chapter three). Minor differences between the reported incidence rates are likely 
to result from the prevalence of risk factors between countries, such as smoking and blood 
pressure, as well as autopsy rates and population structure 1, 3. Finnish studies were previously 
excluded from pooled analyses and their use in reference populations has been questioned 
based on the high reported incidence of aSAH and concerns regarding the external validity 
of the findings 1. This means that the PHASES score is based on a limited number of aSAH 
patients, stratified into multiple subgroups. Aside from the risk of publication bias, this 
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approach might also alter conclusions drawn from pooled analyses such as the PHASES 
risk prediction chart for unruptured intracranial aneurysms, and could consequently lead 
to misguided treatment decisions 1, 2.
The complex pathophysiology of aSAH can also cause systemic organ injury. In a retro-
spective analysis we were able to determine that cardiovascular complications of aSAH are 
associated with prolonged transportation times to specialized care and increased mortality 
(Chapter four). Since early admission did not change the surgical management, it could be 
hypothesized that the early initiation of neuroprotection directed at minimizing EBI-related 
pathophysiological changes might reduce the risk of DCI and subsequently improve patient 
outcomes. Treatments aimed at minimizing early adverse cardiovascular events therefore 
deserve further study.
As rebleeding significantly impairs the prognosis, its prevention is one of the primary goals 
of acute aSAH management 4, 5. Aneurysm obliteration, either by a surgical or endovascular 
approach, definitively prevents rebleeding events, which typically occur within the first six 
hours following ictus and become more frequent the longer that treatment is delayed 4-6. 
Prior to aneurysm repair, factors associated with rebleeding should be avoided and used 
in the clinical risk assessment of individual patients. By performing a meta-analysis of 
the published literature, we revealed that aneurysm size is an important determinant of 
aneurysmal rebleeding (Chapter five); moreover, we were able to demonstrate a volume-
mediated effect of cerebrospinal fluid (CSF) drainage on the probability of rebleeding 
(Chapter six). This necessitates the meticulous control of the amount of CSF drained prior to 
aneurysm closure. Alternatively, it can be argued that patients with large aneurysms, or those 
in need of external ventricular drainage, should undergo emergency treatment rather than 
ultra-early treatment when feasible. Some studies did indeed state that the early treatment 
of a ruptured aneurysm is associated with improved clinical outcomes and a reduction in 
aneurysmal rebleeding rates, with greater benefits using coiling than surgical clipping 7, 8. 
Inconsistent results and heterogeneity between most existing analyses mean it is still unclear 
whether earlier endovascular treatment actually improves outcomes however; in fact, the 
adjusted analysis in one study even suggested that ultra-early treatment may actually expose 
patients to additional harm 6, 9, 10. Indeed, not only is emergency endovascular embolization 
after aneurysm rupture associated with an increased probability of procedural aneurysm 
re-rupture, but these events also correlate with an increase in poor patient outcome and 
mortality overall (Chapter seven). This suggests a shared common etiology between 
procedural aneurysmal perforation and spontaneous rebleeding events, potentially resulting 
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from the delay in EBI recovery during the unstable early phase of the disease. This finding 
adds to the ongoing debate regarding the timing of aneurysm closure, suggesting that extra 
caution might be warranted if emergency aneurysm repair (within six hours) is contemplated. 
Future perspectives
Cerebral circulatory instability during the early course of aSAH complicates its medical 
treatment and concurrent challenges. Hydrocephalus, logistics, and (non-) modifiable 
risk factors expose patients to a heterogenic course of disease; therefore, the preference of 
delaying aneurysm closure until the period of cerebral circulatory instability has passed, 
maintained throughout the 1960s and 1970s by authorities including Drake and Yaşargil, is 
understandable. The focus of future treatments should ideally be on stabilizing the early phase 
of the disease to allow treatment to be delayed; however, the value of pharmacological agents 
in the prevention of aneurysm rebleeding or the amelioration of DCI have been disproven, 
leading to a resumption of momentum toward early surgery. There is little dispute that 
early aneurysm closure reduces management mortality and morbidity rates; however, the 
logic that earlier aneurysm closure results in superior clinical outcomes can be challenged. 
For ischemic stroke, reducing the time to treatment is recommended to improve outcomes. 
Similar to ischemic stroke, the obliteration of ruptured intracranial aneurysms is often 
initiated as soon as feasible to prevent aneurysmal rebleeding; however, endovascular coil 
embolization within six hours of the ictus might expose patients to a higher probability of 
treatment-related aneurysm re-rupture. Early procedural aneurysm re-rupture results in 
increased fatalities and a reduced likelihood of returning to everyday life. Future efforts 
are needed to establish whether the benefits of emergency aneurysm occlusion surpass 
the negative effects of a higher rate of procedural aneurysm re-rupture. If so, it might be 
beneficial to regard aSAH as a neurological emergency analogous to ischemic stroke, in 
which the modern concept of ‘time-is-brain’ leads to immediate endovascular interventions 
with extremely short door-to-repair times.
The risk of aneurysmal rebleeding during hospitalization before aneurysmal closure should 
also be minimized, and the further identification of relevant risk factors will demand the 
use of high-quality (international) registries. Several modifiable factors for rebleeding 
known to be affected by an adequate management strategy also require further study. The 
application of antifibrinolytic drugs (prior to EVD placement) should be discussed, as 
this medication effectively reduces the incidence of rebleeding 11; however, the benefits of 
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antifibrinolytic agents are still inconclusive due to their association with a significantly higher 
rate of DCI and their failure to improve overall survival and functional outcome 11. Their 
efficacy in this situation therefore remains highly speculative. The ultra-early tranexamic 
acid after subarachnoid hemorrhage (ULTRA)-study will investigate whether the ultra-
early administration of tranexamic acid leads so favorable functional outcome 12. Also, by 
defining the volume of CSF drainage that contributes to aneurysm rebleeding, we identified 
a group of patients in need of a currently undefined but much-needed treatment protocol. 
A protocol for a prospective trial evaluating the role of controlled automated CSF drainage 
is currently under development and the study is planned to commence in the near future. 
Conclusion
In this thesis, we evaluated several aspects of the acute management of aSAH, which 
continues to be a critical multifactorial condition involving complex interactions between 
pathological mechanisms. The heterogenic presentation of patients affected by aSAH 
poses challenges for the development of a management protocol for the early course of the 
disease. The primary concern following aSAH is aneurysm closure to prevent aneurysmal 
rebleeding. Although aneurysm closure is of cardinal importance, the optimal timing of 
aneurysmal obliteration may not parallel the treatment of other kinds of stroke as emergency 
endovascular treatments exposes patients with aSAH to a higher rate of procedural aneurysm 
re-rupture. Adverse events during early treatment should be balanced against the probability 
of spontaneous aneurysmal rebleeding during a prolonged waiting period. Amongst other 
factors, aneurysm size, the initiation of CSF-drainage, and the volume of CSF drained prior 
to aneurysm treatment are predictive of spontaneous rebleeding, and can be used in the 
clinical decision-making for individual patients.
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